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A b s t r a c t
Endometriosis is a common condition affecting up to 10% of women of reproductive age. 
Despite being described nearly 150 years ago its aetiology remains unclear. In addition 
there is a clear lack of knowledge of the natural history of the condition if left untreated. 
Numerous medical treatments have been described and are in common use, however the 
evidence for their efficacy at causing disease regression is limited at best.
For endometriotic implants to continue to grow they need to develop additional blood 
supply and their angiogenic potential has been dem onstrated. V ascular endothelial 
growth factor and prostaglandin are, at least in part, believed to be responsible for this. 
Both of these require cyclooxygenase 2 for their production. Oestrogen is also essential 
for the growth of endometriosis and high levels have been demonstrated in endometriotic 
lesions. Local oestrogen production is predom inantly the result of arom atase activity 
which is potently induced by prostaglandin lift. It is thus hypothesised that if the action of 
cyclooxygenase 2 is inhibited, endom etriosis will regress as a  consequence of both 
inhibition of angiogenesis and reduction in local oestrogen concentration.
Based on this theory a randomised double blind placebo controlled trial was undertaken 
to test the hypothesis that valdecoxib (a cyclooxygenase 2 inhibitor) will cause regression
of peritoneal endometriosis in patients with minimal or mild disease over a twelve week 
period.
No significant change in disease quantity was demonstrated compared to placebo. There 
was a consistent (but statistically insignificant) improvement in pain symptoms in those 
subjects taking valdecoxib compared to placebo.
It is concluded that valdecoxib is ineffective at causing disease regression in minimal and 
mild endometriosis.
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Chapter 1 
Introduction
1.1 Background
Endometriosis was first described by Rokitansky in 1860 [1]. It is a comm on condition 
affecting women of reproductive age, characterised by the presence of endometrial glands 
and stroma outside the uterine cavity [2]. Deposits are most commonly found within the 
pelvis [3] however endom etriosis has also been described at sites rem ote from  the 
abdominopelvic cavity including the lung, nasal septum and central nervous system [4-8]. 
Its prevalence ranges from  2-10% [2, 9, 10] in the general population with an increase 
representation in patients presenting with pelvic pain (40-60%) and sub fertility (20-30%) 
[11-13]. There appears to be a genetic predisposition with fam ilial clustering and 
increased incidence am ong first degree relatives with the condition, suggesting a 
polygenic effect rather than a sim ple M endelian pattern [14-16]. Additionally there 
appears to be a racial variation with a decreased prevalence in Africans com pared to 
Caucasians and an increased prevalence in East Asians[17, 18].
1.2 Diagnosis
Presenting symptoms, where present, tend to be either pain [19, 20] and / or sub fertility. 
Pain symptoms include dysmenorrhoea (pain with periods), deep dyspareunia (pain with 
intercourse), chronic pelvic pain, dyschesia (pain on defecation) and occasionally 
dysuria. Symptoms however are often vague and non specific resulting in a mean delay 
from onset of symptoms to diagnosis of 3-11 years [21,22].
The association of endometriosis and fertility is complex. W hilst it is generally accepted 
that there is an association between endometriosis and sub fertility, whether it is a cause
Introduction
2
and effect relationship or sim ply an association by com m on aetiology rem ains unclear 
[23, 24]. M edical therapy to treat endom etriosis appears to confer no benefit on fertility 
[25] how ever surgery does seem to be beneficial [26, 27].
D espite criticism  [28] and lim itations [29-32], laparoscopy remains the ‘gold standard’ 
for diagnosis o f endom etriosis [2] allow ing description o f the lesions or com ponents of 
the lesions into red, black or w hite according to the revised A m erican Society Scoring 
System  [1 1 4 ]. Such inform ation is im portant as, along with quantification o f disease, it 
p rovides in form ation  regard ing  d isease  ac tiv ity , w ith opaque red  lesions being 
significantly m ore active than black, white or non opaque lesions [73,169].
U ltrasound, w hilst extrem ely effective at diagnosing endom etriom as [33] is unable to 
reliably diagnosis peritoneal disease [34]. L ikew ise, m agnetic resonance im aging is 
useful in diagnosing deep disease [35] and adnexal masses [36] but is unable to reliably 
identify peritoneal lesions less than 4m m 2 [37-39]. V arious serum  m arkers have been 
investigated as a m eans o f either diagnosing or m onitoring disease but to date none has 
dem onstrated adequate sensitivity and specificity to be of clinical use [40-47].
1.3 Aetiology
D espite  being orig inally  described  nearly  150 years ago [1] the full aetio logy  o f 
endom etriosis rem ains unclear. V arious theories abound and it appears that the disease 
is m ultifacto ria l in orig in . T he orig inal hypothesis o f Sam pson [48] suggesting  
retrograde m enstruation m ay well be true in part but cannot be the sole answer. N ot 
only is the disease found in sites unaffected by retrograde m enstruation [4-8] but also
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retrograde m enstruation itself occurs in virtually all m enstruating w om en [49-51] yet 
only  2-10%  [2, 9, 10] o f w om en develop endom etriosis. O ther factors key to  the 
developm ent o f endom etriosis include altered im m une response, both cellular [52-63] 
and hum oral [64-68] and the presence o f peritoneal factors that stim ulate / allow  cell 
growth in response to oestrogens [2, 61, 62].
T o  continue to  grow , endom etrio tic  deposits like tum our im plants [69-72], need to 
d e v e lo p  a new  b lood  su p p ly . T h e ir  an g io g e n ic  p o ten tia l and  a sso c ia te d  
neovascularisation have been dem onstrated [73, 74] as well as the fact that angiogenic 
inhibitors inhibit and cause regression of endom etriotic lesions [75 ,76].
Peritoneal m acrophages appear to  play a critical role in the aetiology and pathogenesis 
o f endom etriosis being increased in num ber, concentration and activational status in 
w om en with endom etriosis [77-81] and contributing, at least in part, to soluble growth 
and angiogenic factors present in peritoneal fluid [82-85]. One such factor, vascular 
endothelial growth factor (VEG F), has been shown to be present in significantly greater 
amounts in the peritoneal fluid of w om en with endom etriosis com pared to controls [86]. 
A dd itiona lly , th is study  dem onstra ted  a cyclical varia tion  in  peritoneal V E G F 
concen tra tions in the endom etriosis  pa tien ts , being sign ifican tly  h igher in the 
proliferative phase than the secretory, w hich was not present in the controls. V E G F 
im m unoreactiv ity  has been show n in both ectopic and eutopic endom etrial tissue 
m acrophages, and m acrophages from  these w om en caused V E G F dependent increases 
in endothelial cell p roliferation above that o f norm al w om en [87]. Peritoneal fluid
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m acrophages secrete V E G F in response to ovarian steroids via the f lt l  and kinase insert 
dom ain containing receptors (K D R ), and K D R  receptor expression  and m igratory 
response are significantly higher in w om en w ith endom etriosis com pared to  controls 
[87]. This suggests that ovarian steroids are involved in regulating the secretion o f a 
potent angiogenic growth factor from  peritoneal m acrophages.
In addition to V E G F there is increasing evidence that the enzym e cyclooxygenase 2 
(COX-2) and one o f its m ajor products prostaglandin E2 (PGEft are strongly linked with 
angiogenesis. Cancer cell studies suggest a strong link between COX-2 expression and 
hypoxia induced tum our cell angiogenesis [88] and study in the corneal model has 
shown COX-2 is essential for angiogenesis [89]. The angiogenic potential of PG E2 itself 
has been dem onstrated [90] and it appears that, not only is CO X -2 required fo r the 
production o f PG E2 , but that it is vital fo r the production of V EG F as V E G F knockout 
fibroblasts are unable to secrete V E G F [91]. The fact that expression o f CO X-2 in the 
glandular epithelium  of both eutopic and ectopic endometrial tissue has been shown to 
be greater in patients with endom etriosis than controls [92], suggests CO X-2 has a  key 
role in the angiogenesis associated with endometriosis.
CO X-2 is further im plicated in the pathophysiology of endom etriosis by its ability  to 
induce arom atase activity. The m ost likely m echanism  for this is via the production of 
PG E2 which is a  know n potent inducer o f arom atase [93]. This increases intracellular 
cyclic adenosine m onophosphate (cA M P) w hich stim ulates arom atase activ ity  with 
subsequent increased oestrogen biosynthesis [94-96]. A rom atase, which catalyses the
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conversion o f the androgens androstendione and testosterone to the oestrogens oestrone 
and oestradiol, is expressed in a num ber o f tissues. In the pre m enopausal wom en the 
predom inant source o f oestrogens are the ovaries how ever post m enopausally or post 
oophorectom y extra-ovarian arom atase produced oestrogen becom es m ore im portant. 
Control o f arom atase expression is usually by cA M P regulation in glandular tissue, 
especially the ovary, and by glucocorticoids and cytokines in extra glandular sites such 
as adipose, skin and breast (non-m alignant) [96, 97]. H igh levels o f arom atase m RNA 
have been docum ented in endom etriotic im plants [98] and very high levels of arom atase 
activ ity  have been dem onstrated in endom etriosis derived cells w hen cultured in a 
m edium  containing a cA M P analogue [93]. The levels o f activity  dem onstrated were 
com parable w ith that o f syncytio trophoblast. In addition it has been reported that 
oestrogen itse lf increases PG E 2 production  by stim ulating C O X -2 in endom etrial 
strom al cells [99] thereby  creating  a positive feedback  loop fo r continuous local 
oestrogen and prostaglandin production favouring the proliferative and inflam m atory 
characteristics o f endom etriosis. Further evidence o f this positive feedback and the 
im portance o f arom atase is provided by the occasional persistence o f endom etriosis 
after oophorectom y, and the apparent resolution when treated with arom atase inhibitors 
[100, 101].
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Figure 1. Interaction of COX-2, VEGF, PGE2 and aromatase
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1.4 Natural History
W hilst the lack of understanding of the aetiology of the disease may be explained by its 
overall com plexity, what is less explainable is our far from clear understanding of the 
natural history of this condition. On review ing the published literature there are in fact 
only two papers that state their objective is to study the natural history of endometriosis, 
one o f which is in baboons [102, 103]. Sym ptom s often bear little relationship to 
d isease severity [19] and the presence of endom etriosis may not alw ays be apparent 
from  symptom s. Indeed the condition has been found coincidentally in between 1.6% 
and 7%  of patients undergoing laparoscopic sterilisation [104, 105]. As stated by 
H arrison & K insella [106] ‘To rely on sym ptom s alone to judge efficacy, as done in
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many reports, is unw ise’. From the hum an[103] study it appeared that untreated, 27%  of 
patien ts’ disease spontaneously im proved how ever this was of only eleven patients. It 
has been suggested that all identified endom etriosis should be treated as its is believed 
that untreated disease m ay progress and that predicting in w hom  this m ight happen is 
no t possib le  [103, 107]. B oth  o f these stud ies how ever w ere in  patien ts being 
investigated for sub fertility  so could therefore be considered sym ptom atic. In these 
cases such a policy would seem appropriate. In other situations this m ay not be the case. 
Should endom etriosis be discovered incidentally in an asym ptom atic patient undergoing 
a  laparoscopic sterilisation the situation is very different. Fertility is not an issue and the 
condition, in all but a  very few  cases is self lim ited by the m enopause. A s no treatm ent 
is risk or side effect free then treatm ent in this case would seem inappropriate. The more 
com plicated area is the case o f asym ptom atic incidentally discovered endom etriosis in a 
patient in whom  fertility is desired. The presence of endom etriosis dose not guarantee a 
problem  w ith fertility  but as a  group, patients w ith endom etriosis do have reduced 
fecundity  com pared to those w ithout [108]. A lso  surgical treatm ent o f endom etriosis 
has been shown to increase fecundity  [26]. T he lack of fertility  issues at the tim e of 
surgery m ay sim ply be due to lack  o f attem pt at conception at this stage and thus 
fertility  has not been proven. In this situation an individualised approach would seem 
m ost appropriate with the patient being inform ed of the risks and benefits of treatm ent 
versus no treatm ent. T his is obv iously  considerab ly  ham pered  by the lack  o f 
understanding o f the natural history of the condition left untreated.
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W ith the current evidence available on the benefit of both m edical and surgical 
treatm ents of endom etriosis it is clearly unethical to subject patients to at least two 
laparoscopies without treatm ent and hence such information must be gleaned from  other 
means. The most useful area to find such information is from randomised controlled trials 
(RCT’s) that include a placebo or no treatm ent arm and that use disease status at second 
look laparoscopy as an end point. The paucity o f any R C T’s has previously been 
highlighted [109-111] and those that are truly controlled with a non treatment or placebo 
are even fewer.
Assessm ent and description o f endom etriosis is usually performed using the American 
Fertility  Society Scoring system  (rAFS) [112-114]. Originally developed to try to 
correlate disease with fertility it is heavily w eighted for disease of the ovaries and 
fallopian tubes and relatively insensitive to peritoneal disease. Severity o f disease as 
assessed by this score has little correlation with the severity of symptoms [19, 115]. 
W hilst current symptoms are clearly the main concern of the patient there is concern that 
to rely on these alone as a guide to disease control may allow the disease to progress 
insidiously such that delayed surgery may be much more complex and hazardous than if 
the procedure was carried out earlier. As such studies of any new treatm ents, whilst 
obviously having to show symptomatic relief, should also be able to demonstrate disease 
regression (or at worst stasis) if they are to be relied upon for endometriosis treatment. If 
carried out appropriately, studies of new therapies should be able to dem onstrate an 
objective assessm ent of efficacy or otherwise of intervention. It has been shown that 
treatm ent of endometriosis by both medical and surgical means has a placebo effect of
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around 20-25% [43, 116, 117] when symptoms are assessed alone. In view of this, any 
studies investigating treatments of endometriosis must have a placebo group for control if 
the efficacy of therapy is to be truly demonstrated.
1.5 T rea tm en t 
Medical Treatments
The firs t m edical treatm ent o f endom etriosis involved the creation o f a  ‘pseudo 
pregnancy’ [118] as it was noted that the condition improved during and following 
pregnancy. All currently available medical treatm ents involve hormonal m anipulation 
some of which still rely on the high continuous progesterone ‘pregnancy like’ state.
Categories of drugs used at present are;
P rogestagens - T hese drugs have ‘p rogeste rone  lik e ’ ac tiv ity  and include 
m edroxyprogesterone acetate, norethisterone and dydrogesterone. A recent Cochrane 
review has concluded the continuous progestagens appear to be effective in the treatment 
of painful symptoms of endometriosis [119]. There are few controlled studies assessing 
their effectiveness at causing disease regression and this question is addressed in chapter 
2.
Com bined oral contraceptive pill (COCP) - These consist of a synthetic oestrogen 
(usually ethinyl estradiol) and synthetic progestagen given in a continuous or cyclical 
fashion. Their prim ary use is as an anovulatory m ethod of contraception however, 
because of their ability to induce endometrial atrophy, they are used in endometriosis. 
T here is relatively little evidence fo r efficacy in treating painful sym ptom s of
Introduction
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endometriosis and a recent Cochrane review concluded there is a paucity of data but that 
the data supports the use of this treatm ent as a first line therapy for treatm ent of painful 
symptoms of endometriosis [110]. The only study included in this review showed a 74% 
im provem ent in symptoms [120] and a further study has shown a 70%  improvement
[121]. No controlled trials exist assessing the efficacy of the COCP in causing disease 
regression.
Danazol - This is a drug with androgenic and progestagenic activity. It is effective at 
treating painful sym ptom s of endom etriosis but is lim ited by the occurrence of 
androgenic side effects [111]. Its efficacy at causing disease regression as compared to 
placebo is only addressed in one trial and this is discussed in chapter 2 [117]. 
G onadotrophin horm one (GnRH) agonists - This group of drugs induce a state of 
hypogonadotrophic hypogonadism  by continuous stim ulation of the pituitary GnRH 
receptors. They include Goserelin, Buserelin, Leuprorelin and Triptorelin and in a recent 
Cochrane review were shown to be effective at treating pain symptoms of endometriosis
[122]. This review however also concluded GnRH agonists were no more effective than 
progestagens, CO CP or danazol and that they produced m ore hypo-oestrogenic 
symptoms. Their efficacy at causing disease regression as compared to placebo is only 
addressed in one trial and this is discussed in chapter 2 [123].
By the very nature of the drugs affecting the endocrine system they are associated with 
various, often unacceptable, side effects including androgenising symptoms [124], weight 
gain, menopausal symptoms and in longer term  use, loss of bone density [125-140]. All 
m arkedly reduce fertility for the duration of their use and in the case of the androgenic
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drugs may also be teratogenic should a pregnancy occur. Additionally, in those patients 
trying to conceive, fertility is not im proved post treatm ent. M edical treatm ent, therefore, 
has no role in the treatm ent o f endom etriosis associated sub fertility as it simply delays 
conception and / or ongoing fertility treatm ent [25 ,127 , 128, 136, 141-145].
Sym ptom atic im provem ent in pain w ith such treatm ents range from  60%  -100%  
depending on the pain being assessed. Regim ens causing am enorrhoea obviously have a 
profound effect on dysm enorrhoea but less effect on chronic pelvic pain or dyspareunia 
[106, 115, 120, 121, 127, 140, 142, 146-155]. Relapse is how ever com m on, w ith rates 
quoted at 20%  at six m onths [136], around 50%  at one year [144, 148] and between 33- 
74.4%  after 3-5 years [40, 156, 157]. This is probably due to therapy suppressing the 
endom etrial deposits during treatm ent, ra ther than eradicating them , as quiescent 
d isease has been dem onstrated  in v irtually  all w om en treated  w ith progestagens, 
danazol and GnRH agonists [158]. Reactivation can then occur on cessation of therapy.
T he effect of medical treatm ents in causing disease regression is how ever far less clear. 
Few studies have a placebo group and even less also include quantification of disease as 
an endpoint. This question will be addressed later in this thesis.
Surgical Treatments
Surgical treatm ent o f endom etriosis m ay be conservative, involv ing  the surgical 
destruction or removal o f endom etriotic deposits, up to a radical total hysterectom y with 
bilateral salpingo-oophorectom y. T he aim  of conservative surgery is to rem ove all
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visib le d isease and restore the pelvic anatom y to norm al. Such surgery has been 
dem onstrated to provide good sym ptom atic relief as well as im prove fertility [27, 109]. 
R elapse rates range from  13.5 % to 40.3%  at 3-5years [159-161] which m ay be due to 
either new disease, growth o f previously m icroscopic deposits that were not visible at 
the tim e of surgery or incom plete treatm ent of deposits that were present.
1.6 Summary
Endom etriosis is a  com m on condition o f m ultifactorial aetiology. C urrently available 
trea tm en ts are o f variab le  and questionab le  efficacy  and the m ajority  produce 
unpleasant side effects and/or require invasive procedures. New treatm ents are required 
that not only treat sym ptom s o f the disease but also cause disease regression. Ideally 
these should cause less side effects, preferably not cause endocrinological change and 
there by possibly enhance rather than reduce fertility.
1.7 Introduction to layout of thesis
From  the introduction it is apparent that num erous questions rem ain to be answ ered 
with regard o f endometriosis.
A s outlined, it is o f critical im portance to know if m edical treatm ent o f the d isease 
actually  causes disease regression. This is addressed in chapter tw o by a system atic 
review  of all published random ised controlled trials o f any medical treatm ent that used 
change in disease as an end point.
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The question of natural history o f this condition is also of vital im portance in both 
understanding the condition itself and also counselling patients with endometriosis. The 
paucity of knowledge in this area has been explained. In chapter three, using the placebo 
arms of randomised controlled trials that used change in disease as an end point, and in 
com bination with the placebo group of the study in chapter five, attem pts have been 
made to try and define the natural history of the condition. By combining data, as much 
as statistically  feasible, I have attem pted to quantify the risk o f progression and 
regression when the disease is left untreated.
Because of the insensitivity of the rAFS scoring system in defining change in peritoneal 
disease, in chapter four I have described and tested a new m ethod of quantifying 
superficial peritoneal disease. Using digital photography and a specifically designed 
computer analysis package the reproducibility of this technique has been demonstrated.
Chapter five is a random ised placebo controlled trial of a COX-2 inhibitor, for the 
treatment of endometriosis using disease regression as a primary end point. This uses the 
quantification method described in chapter four as well as the rAFS score.
Chapter six is a summary of the finding of the preceding chapters, their strengths and 
weaknesses and recommendations for further study.
Introduction
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Systematic Review of medical treatments
C h a p te r  2
Systematic review of medica! treatment
A systematic review was conducted to determine the effectiveness of medical therapies at 
causing disease regression in endometriosis. Because of uncertainty about the natural 
history of the condition, only studies in whom there was a placebo or no treatm ent arm 
were included, as to compare two treatm ents with each other is meaningless unless one 
knows what will happen to the condition without any intervention.
2.1 Method
A im : To determine the efficacy o f medical therapies at causing disease
regression in endometriosis 
Population: Patients with laparoscopically confirmed peritoneal endometriosis
Intervention: Any medical treatment of endometriosis
Outcome measures: D isease regression as assessed by any quantitative or semi
quantitative means.
Study types: Randomised controlled trials
Exclusion criteria: Studies with no placebo or ‘no treatment’ arm
Non randomised trials
Trials not using disease regression as an end point
Search Strategy:
The primary search strategy was an electronic search of Medline 1951- to date, EM BASE 
1974 to date and the Cochrane Database of Systematic reviews. Searches were conducted 
using the M eSH terms endometriosis, randomised controlled trial, randomized controlled 
trial, random allocation, drug, and pharmaceutical preparation . A  Keyword search was
16
also performed using the terms endometriosis, randomised controlled trial, randomized 
controlled trial and drug. In all cases studies were limited to human.
Secondary reference searching was undertaken by reviewing the reference list of cited 
articles as well as the relevant Cochrane database reviews [25, 110, 111, 119, 122].
2.2 D escrip tion an d  a p p ra isa l o f studies
The search strategy identified six studies, one of which was excluded as it was not 
randomised [103]. Three studies used progestagens. One compared medroxyprogesterone 
acetate with placebo [106], one m edroxyprogesterone acetate and danazol and placebo 
[117] and one dydrogesterone and placebo [115]. There was one study com paring 
gestrinone with placebo [107] and one com paring the GnRH agonist triptorelin with 
placebo [123], All used the A m erican Fertility Society scoring system, either original 
[113] or revised [114],to define disease status and in the Bergqvist [123] study number of 
lesions and surface area was also assessed.
A summary of participants in each study is shown in table 2.1 and the changes in rAFS 
scores in table 2.2
Systematic review of medical treatment
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Systematic review of medical treatment
Table 2.1 Numbers and entry criteria for each study
Study Nos.
recru
ited
Nos.
rando
mised
Nos.
completed 
to second 
laparoscopy
Participants Exclusion criteria
Harrison
[106]
100 100 90 20-39yo 
Infertility 
>2yrs (no other 
others cause 
found) 
rAFS I-IV
Ovarian, uterine, tubal defect 
History of Cancer 
Renal/Hepatic impairment 
Diabetes
Patient received treatment for 
endometriosis within 4  weeks 
of baseline
Overton
[115]
67 62 39 21-42yo 
rAFS I-II 
Patients with 
pain and/or sub 
fertility
Patients taking hormonal 
medication, corticosteroids, 
danazol, GnRH agonists
Telimaa
[117]
59 59 51 Old AFS score 
I I I
No mention of 
indication for 
laparoscopy
Not stated
Thomas
[107]
40 40 35 Old AFS score 
M I
Sub fertility 
patients 
No other 
symptoms of 
endometriosis
Patients with disease that 
mechanically impeded 
fertility
Bergqvist
[123]
49 49 46 rAFS I-IV 
(only one 
patient with 
stage IV) 
Patients with 
symptomatic 
endometriosis
Patients taking OCP or 
steroids within 3 months of 
commencing study 
Patients using long acting 
depot gestagens of GnRH 
agonists within 6 months of 
commencing study 
Patients who had been 
pregnant of breast fed within 
3 months of commencing 
study
History of osteoporosis 
History of coagulation 
disorders
Patients with adhesions 
making laparoscopic 
inspection difficult
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Table 2.2 Affect of treatment on AFS / rAFS scores
Study Intervention Elimination
of disease
Reduced 
AFS (incl. 
Elimination)
No 
change 
in AFS
Increased
AFS
Harrison[106] MPA 50mg/d 
n=47
55%(26) 32%(15) 13%(6)
Placebo n=43 63%(27) 28%(12) 9%(4)
Overton[l 15] Dydrogesterone 
40mg/d (luteal) 
n=14
50%(7) 14%(2) 36%(5)
Dydrogesterone 
60mg/d (luteal) 
n=10
20%(2) 50%(5) 30%(3)
Placebo n=15 53%(8) 20%(3) 27%(4)
Telimaa[117] Danazol 200mg 
tds n=18
39%(7) 61% (11) 39%(7) 0
MPA lOOmg/d 
n=16
50%(8) 62.5 %(10) 37.5%(6) 0
Placebo n=17 12%(2) 18%(3) 59%(10) 24%(4)
Thomas[107] Gestrinone 2.5mg 
2xwk n=18
50%(9) -not 
11 from 
table in 
paper
83%(15) 17%(3) 0
Placebo n=17 18%(3) -not 
4  from table 
in paper
29%(5) 24% (4) 47%(8)
Bergqvist[123] T riptorelin3.75mg 
four weekly n=23
24%%(4) ? 17%(3)
Placebo n=23 4%(1) 52%(12)
Harrison study
The study by Harrison[106] was a single centre random ised, double blind placebo 
controlled trial comparing 50mg of medroxyprogesterone acetate (MPA) with placebo for 
the treatm ent of endometriosis. Random isation was by a block design administrated by 
the pharmaceutical company supporting the project. Disease progression, assessed by the 
revised Am erican Fertility Society score (rAFS), was a primary end point. Numbers, 
participants and exclusion criteria are shown in table 2.1. Patients underwent a diagnostic
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laparoscopy at which time a rAFS score was calculated. Patients were subsequently 
invited to take part in the study. Recruited patients commenced either M PA or placebo 
for tw elve weeks. It is not stated what the interval was betw een the laparoscopy, 
recruitm ent and com m encem ent of treatm ent. Patients were reviewed four weekly for 
clinical assessment. The second laparoscopy was performed between 16 and 24 weeks 
from  the com m encem ent o f study m edication i.e. 4-12 weeks post treatm ent. Further 
clinic visits were also undertaken at 24 and 36 weeks post com m encem ent of study 
medication.
There was no significant difference in baseline demographics of rAFS score bar the MPA 
group having twice as many patients with previous pregnancies and the placebo group 
having more than double the number of patients with a previous history of endometriosis. 
The outcom e of this study was that there was a significant improvement in rAFS score 
and stage in both groups but there was no significant difference in the two groups. The 
figures are shown in table 2.2. O ther outcom es were a trend to an im provem ent in 
menstrual symptoms in the M PA group and a significant improvement in the ‘assessors’ 
evaluation of patient well being.
Overall this is a very well designed study. The increased numbers of women with 
previous pregnancies at baseline in the M PA group probably had little bearing on the 
final outcome as pregnancy was not used as an end point. The higher number of women 
in the placebo group who had a previous history of endom etriosis however may be 
relevant. Endometriosis is a condition that, in many women, may recur. Indeed there are
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som e patients w ho respond to w hichever treatm ent they are given and never have 
further sym ptom s w hile others appears to relapse tim e and tim e again. If  we assum e 
those w ho have been diagnosed w ith endom etriosis previously have been treated in 
som e way they m ust have relapsed to be in the study. A s such these m ay slightly bias 
the results in that they m ay be less likely to spontaneously regress than patients who 
have been newly diagnosed. If  this were the case it may be the spontaneous regression 
rate seen in the placebo group w ould be even greater if only new ly diagnosed cases 
were included.
The use of high dose M PA continuously w ould be expected to  cause am enorrhoea in a 
sign ificant proportion o f patients. U nfortunately  the rates o f am enorrhoea are not 
docum ented but it is noted that 98%  of patients in the M PA  group noted a change in 
m onthly loss (presum ably reduced) com pared w ith only 25%  in the placebo group. 
Such dram atic changes would be so apparent as to effectively ‘ unblind ’ both the subject 
and the investigator. It is interesting to note that there was a significant im provem ent in 
assessors perception o f patient ‘w ellbeing’ and it is quite possible that the effective 
unblinding by am enorrhoea lead to unconscious bias on the part o f the assessor. Clearly 
how ever, if such bias did exist it was not great enough to cause a significant difference 
in M PA  over placebo.
O verton study
T he study by Overton[115] was a random ised , double blind, placebo controlled, three 
centre trial. The study investigated the efficacy of two doses of dydrogesterone (40mg
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and 60mg/day) compared to placebo when taken in the luteal phase of the menstrual 
cycle. Details of participants and numbers are shown in table 2.1.
Subjects were recruited to the study w ithin three m onths of having a diagnostic 
laparoscopy at which a rAFS score was assigned. Random isation was by com puter 
generated random numbers. Baseline demographics were similar in each group. Patients 
kept menstrual and pain diaries from one month before treatment to the completion of the 
study. Treatment was continued for six months and a second laparoscopy was undertaken 
within three months of completion, at which time a further rAFS score was calculated.
Change in rAFS score was the primary end point and the study did not demonstrate a 
significant difference in change of rAFS between the two groups. Details of changes in 
rAFS scores in each group are shown in table 2.2. 94% of the women reported acceptable 
bleeding patterns with 3 reporting longer than average cycles and 2 reporting irregular 
bleeding (all five of which were receiving dydrogesterone). The only notable significant 
change was a reduction in pain from month one to month six in the group receiving 60mg 
dydrogesterone. Additional comments in the discussion highlight the fact that pain was 
not related to rAFS score or change in score and the rAFS score was insensitive with 
respect to change in disease especially in patients with mild disease.
This was a very well designed study. The fact that the dydrogesterone was only given in 
the luteal phase would not have significantly changed the menstrual pattern in any of the 
groups so both the patient and assessors would have remained blinded throughout.
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The fact that patients were recruited to the study up to three m onths after the initial 
laparoscopy, at which the rAFS score was calculated, was not ideal. The rAFS score by 
the time of recruitment to the trial may well have changed and hence the change in score 
from  baseline in each group may not be correct. The exact tim ing o f the second 
laparoscopy was also rather vague in the methodology being within three months of the 
completion of treatm ent and more detailed figures of exact timing are not given in the 
results section. The tim ing of the laparoscopy is actually very im portant as there is 
concern that a laparoscopy carried out very soon after the end of treatm ent may miss 
quiescent disease that has been suppressed by treatment. Reactivation on cessation of 
treatm ent may mean disease was more apparent if the laparoscopy was carried out with a 
greater interval [162].
A t first inspection there does appear to be a relatively high dropout rate with only 39 of 
the 62 patients originally randomised completing to the point of second laparoscopy. The 
authors have however given adequate inform ation to explain this. The dropout rate is 
higher in the treatm ent group than the placebo group being 10/20 in the 60mg group, 
14/23 in the 40m g group and only 4/19 in the placebo group. The m ajority of these 
dropouts however were because the patients conceived (11/43 in treatm ent groups and 
2/19 in the placebo group). As many of these patients were suffering from infertility and 
knowing that there is an association between endometriosis and sub fertility [108] the fact 
that 13 conceived is a positive response. As none of these patients were re-Iaparoscoped 
their rAFS scores are not available, but it may well be that these in fact responded very 
well and that not being able to include them  in the final rAFS figures has m asked a
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significant improvement in the disease. As most came from the treatment group this may 
bias the results against this group.
Telim aa study
The study by Telim aa[117] was, by com parison to the other studies included in the 
review, of relatively poor quality. It was a randomised, double bind, placebo controlled, 
single centre study comparing the efficacy of danazol (200mg tds), medroxyprogesterone 
acetate (lOOmg/day) and placebo, taken for six months, in the treatment of endometriosis. 
Details o f participants and numbers are given in table 2.1 although it is noted that the 
indication for laparoscopy in these patients is not described in this paper. Additionally 
there is no mention of exclusion criteria.
Patients underwent a  laparoscopy at which time an AFS score was calculated. A t the 
same time electrocoagulation was used to treat to some lesions in 14 (24%) patients, who 
are still included in the analysis. Patients were random ised to one of the three groups 
however the method of random isation is not stated. Study m edication was commenced 
on the first day of m enstruation following the laparoscopy. Patients were then seen at
1,3,6 and 12 months from the com m encem ent of treatm ent for clinical assessm ent and 
assessm ent of pain symptoms by a four point numerical scoring scale. Six months after 
cessation o f treatm ent i.e. around one year from the beginning of the study, a second 
laparoscopy was performed and the AFS score calculated again. The same physician 
undertook all the laparoscopies.
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The groups were com parable in baseline dem ographics however, despite the authors 
stating there were no differences in severity of peritoneal disease between the two groups, 
no patients in the placebo group had stage two disease compared with 4  in the MPA 
group and 7 in the danazol group. Additionally it was noted that, at randomisation, those 
allocated to the danazol group had more ovarian endometriomas and as such the authors 
opted not to include changes in ovarian endometriosis in the analysis. Change in AFS 
score was the primary end point in this study, the figures for which are shown in table 
2.2. Resolution of disease (AFS score 0) occurred statistically significantly more often in 
both the M PA group and danazol group compared to placebo and there was no difference 
in disease resolution between M PA and danazol. In those patients treated with diathermy 
at first laparoscopy the effects on AFS at second laparoscopy are shown in table 2.3.
T ab le  2.3 Change in AFS score in patients treated with electrocoagulation
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Reduced AFS 
(incl. resolution)
No change 
in AFS
Increased
AFS
M PA n=5 3 2 0
Danazol n=4 2 2 0
Placebo n=5 2 2 1
M ean pain scores for pelvic pain, low back pain, defecation pain and total pain were 
significantly reduced in both the M PA and danazol groups com pared to placebo with 
there being no significant difference between M PA and danazol themselves.
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The most obvious critique o f this paper is that 24% of the patients received additional 
treatm ent to their endometriosis in the form  of electrocoagulation. These patients were 
treated early on in the trial and were those with easily accessible minimal or mild disease. 
Thus these patients had ‘different’ disease to those untreated or recruited later in the 
study. It may be that this disease may behave differently to the same disease elsewhere. 
By chance, one assum es, the num bers treated with additional electrosurgery in each 
group are about the same (table 2.3). It is reasonable therefore to compare the results of 
the groups with each other but one cannot conclude that any single medical treatment in 
the trial is effective or ineffective if some of the subjects had additional treatment. It may 
be that it is only the combination of these two treatments that was effective in these cases 
and that either treatment alone may not have had the same effect.
The lack of explanation of random isation method is also of concern as such information 
is essential to ensure lack of bias in treatment allocations.
No mention is made in the paper as to effect on subjects menstrual cycle, however, with 
both M PA and danazol administered in this way one would expect most if not all of these 
subjects to become amenorrhoeic. As such this would clearly unblind both the patient and 
the assessor again leading to the potential for bias.
The removal of ovarian endometriosis from the analysis because the danazol group had 
greater numbers of endom etriom as is questionable. The ovary is a com m on site for 
endom etriosis and to  exclude all this disease risks loosing potentially  valuable
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information. This anomaly in baseline characteristics could have been managed using 
some form of multiple regression analysis to allow correction of this imbalance.
This paper is included in this systematic review as it meets the search criteria however 
there are major flaws in its design and as such its results should be viewed with caution.
Thomas study
Thom as’s study was the first randomised, placebo controlled trial into any treatm ent of 
endom etriosis. It was a single centre double blind trial investigating the efficacy of 
gestrinone (2.5mg twice weekly for 24 weeks) in treating asymptomatic endometriosis. 
Participants and numbers are shown in table 2.1.
Patients underw ent a laparoscopy and AFS scoring. They were then random ised to 
receive gestrinone or placebo although the method of randomisation is not described. The 
tim e from laparoscopy to com m encem ent of treatm ent is also not stated. Patients were 
reviewed monthly and underwent a second laparoscopy during the last week of treatment. 
During this laparoscopy the assessor was unaware of the previous AFS score and the 
patients menstrual history. An AFS score was performed at this laparoscopy.
Change in AFS score was the primary outcome in this study and the figures for this are 
shown in table 2.2. The AFS score was noted to be significantly less in the gestrinone 
group at random isation and thus change in AFS score was compared between the two 
groups. There was a significantly greater reduction in AFS score in the gestrinone group
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com pared to the placebo group and the frequency of deterioration was significantly 
greater in the placebo group compared to the gestrinone group.
The authors comment in the discussion that, untreated, a significant num ber of patients 
will have progression of disease and that it is not possible to define who these patients 
are. They thus suggest that treatment should be given to all patients with laparoscopically 
diagnosed disease.
Overall this is a well designed study. Efforts have been made to try to overcom e the 
‘unblinding’ effect of changes to m enstruation that can occur in gestrinone by the 
assessor being unaware of the patients’ menstrual history at the time of laparoscopy. In 
fact only 8 of the 18 gestrinone treated patients became amenorrhoeic. Clearly it is not 
possible to blind the patient in this circum stance, however as the end point was AFS 
score and not subjective assessment by the patient, this is not a major concern.
There does appear to be an error in the figures quoted for disease elimination in table III 
of the paper. In this table it is stated that disease elimination occurred in 4  patients treated 
with placebo and 11 treated with gestrinone. However on reference to the raw data in 
table II assuming disease elimination is represented by an AFS score of 0 then in fact the 
true rates of elimination were 3 in the placebo group and 9 in the gestrinone group. These 
figures are shown in table 2.2.
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The fact that the laparoscopy was carried out in the final week o f treatm ent may have 
over estim ated the efficacy o f gestrinone. As stated earlier, it is possible that disease, 
whilst still present, may be quiescent and thus not visible at laparoscopy but that this may 
reactivate once hormonal manipulation is ceased[162].
Bergqvist study
Bergqvist’s study[123] was a three centre random ised double blind placebo controlled 
trial investigating the efficacy of the GnRH agonist triptorelin (3.75mg monthly for 6 
months) in treatm ent of pain symptoms of endometriosis. Change in rAFS score was a 
secondary end point. Participants and number are shown in table 2.1. Patients underwent 
a diagnostic laparoscopy during which a rAFS score was calculated. A dditionally the 
num ber of lesions were counted and an assessm ent of surface area was made using a 
measuring probe. The exact details of how the latter was performed is not fully explained. 
Patients were randomised by separate randomisation in each centre although the method 
of random isation is not stated. Treatm ent was com m enced within one m onth of the 
laparoscopy with the first injection being given between day one and four of the next 
menstrual cycle. Patients were reviewed by a study nurse at 2, 4, and 6 months after 
starting treatm ent and were required to keep a diary of their bleeding pattern, analgesic 
requirem ents and any adverse incidence. Additionally, their pain was assessed by both 
visual analogue scales for pelvic pain, dysm enorrhoea and dyspareunia and by the 
Duration Intensity Behaviour Scale (DIBS). The second laparoscopy was undertaken four 
to six weeks after the last injection i.e. zero to two weeks after the injection should have 
begun to stop working, at which an rAFS score was calculated. Follow up was continued
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with visits at 9,12,15,18,21 and 24 months after starting medication with the DIBS being 
completed at each visit. Recurrence was defined as the ‘first time a patient experienced a 
DIBS rated pain that was at least as severe as before therapy’.
The results with regard to rAFS scores at laparoscopy are shown in table 2.2. As this was 
not a primary outcome not all the information with regard to change in score is available 
and the raw data is not presented in the paper to allow calculation. W ith regard to pain 
triptorelin significantly reduced pain as assessed by DIBS compared to placebo over the 
first six months and there was no significant change in pain in the placebo group in the 
first six months. The mean rAFS score reduced by 50% in the triptorelin group and 
increased by 17% in the placebo group however the ranges / confidence intervals are not 
given and there is no m ention as to whether this achieved statistical significance. The 
average surface area of endometriosis reduced by 45% in the triptorelin group with no 
change in the placebo group although the figures are not given and there was no change 
in the number of lesions in either group. The post operative follow up was very poor with 
only 8 patients (5 from  triptorelin and 3 from  placebo group) com pleting. As such, 
evaluation of these figures is meaningless.
The main problem with this study with regard to inclusion in this review is that change in 
rAFS score was only a secondary end point and hence the data is not complete in some 
cases and rather confused in others. In the abstract for example it states that ‘the extent of 
endom etriotic lesions was reduced by 50% during triptorelin treatm ent and increased
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17% during placebo’ however these figures are not apparent in the results section at all, 
making it difficult to assess how they were derived.
The issue of unblinding by amenorrhoea is also true of this study. By two months none of 
the wom en in the triptorelin group were m enstruating making treatm ent allocation 
obvious to both patient and assessor. Additionally, as dysmenorrhoea is used as one of 
the prim ary end points, it is obvious that such a condition is im possible in an 
am enorrhoeic patient giving a profound difference in those treated w ith triptorelin 
compared to those treated with placebo.
The classification of the disease in the patients also seems slightly erroneous. In the 
methodology it is stated that only one patient had severe (stage IV) disease and the rest 
all had mild to moderate. In fact 25 patients had minimal (stage I) disease and only 22 
had mild or moderate disease (stages II and III).
The m ethod used to determine surface area is extremely vague. This is not a technique 
used in standard practise and therefore one would expect the technique to be explained in 
some detail. Additionally, some m ethod should have been undertaken to validate such a 
techniques both in terms of accuracy and reproducibility. As the assessors were also 
certain ly  inadvertently  unblinded  (by am enorrhoea) and the technique appears 
unvalidated these result should be viewed with great caution.
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As with several of the other studies the fact that the second laparoscopy was carried out 
four to six weeks after the last injection may lead to the under diagnosis of the disease in 
the triptorelin group. Additionally, as this drug is given as a depot its effects will not stop 
im m ediately four weeks after the last injection but will slowly reduce in efficacy 
allowing ovarian function to resume. Thus by six weeks after the last injection there is 
still likely to be some triptorelin activity.
The definition used for recurrent disease is also questionable. The definition relies solely 
on symptoms, but as is shown from studies in this review as well as other papers[19] 
symptoms often bear little correlation with disease status. As the drop out rate in the 
follow up group was so poor no major inferences have been drawn from this group in any 
case.
For all studies included the dropout rates have been outlined and the marked variability in 
these has been discussed. A s disease regression is an end point w hich requires 
laparoscopy it obvious that no disease regression data is available for the ‘dropout’ 
patients. As such, the data presented is the efficacy of treatm ent in the com pliant / 
uncomplicated patients and not the efficacy of treatment as a whole. In other words these 
figures are ‘per protocol’ results rather that intention to treat results. It is therefore 
important to be aware that such analysis tends to over estimate the efficacy of a therapy 
compared to what would be expected in clinical practise.
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Despite an extensive search and including any medical treatm ent, there are very few 
random ised placebo controlled trials assessing the efficacy of m edical therapies in 
causing disease regression in endom etriosis. The five studies identified here are of 
variable quality as outlined in the critique of each paper.
W ith regard to the efficacy of the progestagens M PA and dydrogesterone (used in the 
luteal phase), the two good quality studies of Harrison and Overton would suggest they 
are no better than placebo at causing disease regression. MPA when used in Telim aa’s 
study did appear to show improved disease regression compared to placebo however, as 
outlined, this study has m ajor flaw s and its conclusions do not carry the validity of 
Harrison's. As such on current evidence one can conclude there is no good evidence that 
M PA  or lu teal phase dydrogesterone  cause sign ifican t d isease regression  in 
endometriosis.
The results as to efficacy of danazol are limited by the fact that the only study addressing 
it is Telim aa’s study which is flawed. The fact that the MPA component of this study 
contradicts the methodologically superior study of Harrison must lead one to question the 
validity of the danazol component of this study. Thus it difficult to draw firm conclusions 
from  what is available and one cannot conclude that danazol is effective based on this 
study alone.
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Accepting the limitations of the Thomas study, the overall high quality of the trial would 
allow one to conclude that gestrinone is effective in causing disease regression in 
endometriosis. Clearly the fact that only one study exists testing this hypothesis and that 
the numbers are small, means this result should be accepted with caution.
The efficacy of triptorelin in causing disease regression is not proven by Bergqvist study 
with no statistical analysis showing a significant improvement in disease status. W ith the 
figures being so vague one must conclude from the evidence available that its efficacy is 
unproven.
It is important to be aware that these conclusions can only be drawn from the published 
literature and there is always the possibility of under reporting of negative studies. It is 
possible, because negative results studies may have remained unpublished, the efficacy 
o f drugs in causing disease regression in endom etriosis are even less than is apparent 
from this review.
2.4 Conclusion
These studies allow us to conclude that M PA and luteal phase dydrogesterone are 
probably ineffective at causing disease regression in endometriosis whilst gestrinone 
appears to be effective. The effects of danazol and triptorelin are inconclusive.
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Chapter 3  
The Natural History of Endometriosis
Natural history of endometriosis
3.1 Introduction
A s alluded to previously, the natural history of untreated endom etriosis is far from clear. 
To try  and outline the natural h istory o f endom etriosis I undertook  analysis o f the 
placebo groups of R C T’s in which change in disease was used as an endpoint.
3.2 Method
D ata from  the placebo groups o f the R C T ’s identified in chapter 2 was extracted from  
the papers. A dditionally , a  fu rther search w as perform ed to  identify  R C T ’s with a 
placebo arm  and second look laparoscopy using rAFS as an end point (i.e. not ju s t those 
in w hich drugs w ere used as in chap ter 2). O nly one study w as identified  [163] 
however, it was not suitable to be included in analysis as only patients who continued to 
have sym ptom s w ere re-laparo scoped . T hese  w ere analysed  s ta tis tica lly  fo r 
heterogeneity using Chi-Square analysis. A ttem pts were m ade to draw  conclusions on 
the d isease behaviour prior to  the assessm ent o f the valdecoxib study using binom ial 
probability. The results of the placebo group from  the valdecoxib study (chapter 5) were 
then  com pared w ith the o ther R C T ’s and, w here possib le, incorporated  to allow  
conclusions to be drawn as to the ‘behaviour’ o f untreated endometriosis.
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The details of the studies included are outlined in chapter 2. As some studies used the old 
AFS [113] scoring system and others the revised AFS [112, 114] scoring system, the 
results have been grouped into progressed (higher AFS score), unchanged and regressed 
(lower AFS score). A summary of the change in rAFS score in the placebo group of each 
paper are outlined in table 3.1.
3.3 Results
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Table 3.1 Summary of placebo groups in each study
Author n AFS
stages
Included
Duration
between
laparoscopie
s
Progress U nchan
ged
Regress Notes
Harrison
[106]
43 1-3 16-24/52 4/43 12/43 27/43
Thomas
[107]
17 1-2 (old 
AFS)
24/52 8/17 4/17 5/17
Bergqvist
[123]
23 1-3 30/52 12/23 11/23 No av. 
Change in 
SA
Overton
[115]
15 1-2 6/12 4/15 3/15 8/15
Telimaa
[117]
17 1-2 (old 
AFS)
6/12 4/17 10/17 3/17 Diathermy 
used in 
some
M ahmood
[103]
11 1-3 12/12
(9-15/12)
7/11 1/11 3/11
Because it was not possible to separate the unchanged and regressed group in the
Bergqvist paper it could not be included in further analysis.
To test for heterogeneity a 3 x 5 chi-square test was performed on the remaining five 
studies as shown in table 3.2
Table 3.2 Chi Sq test of studies excluding Bergqvist
Study Progressed Unchanged Regressed Total
Harrison [106] Observed 4 12 27 43
Expected 11.2 12.5 19.2
Thomas [107] Observed 8 4 5 17
Expected 4.4 4.9 7.5
Overton [115] Observed 4 3 8 15
Expected 3.9 4.3 6.7
Telim aa [117] Observed 4 10 3 17
Expected 4.4 4.9 7.5
M ahmood Observed 7 1 3 11
[103]
Expected 2.8 3.2 4.9
Total 27 30 46 103
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Chi Sq= Tf Observed -  Expected)2 = 28.6 
Expected
W ith 8 degrees of freedom this gives p=0.000 D F=(r-l)(c-l)
Using this as a test of association or non-independence, in table 3.2 there is a highly 
significant difference between the studies in the proportions in the different groups, a size 
effect which than would not be expected by chance. In other words, there is marked 
heterogeneity among these studies. The major contributor to the heterogeneity appears to 
be the Harrison study which has very few progressing and a large number regressing as 
can be seen by the large difference between the observed and ‘expected’ values based on 
the 3x5 contingency tables. The test was thus repeated excluding this study as shown in 
table 3.3.
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T able  3.3 Chi Sq test with Harrison excluded
Study Progressed Unchanged Regressed Total
Thomas [107] Observed 8 4 5 17
Expected 6.5 5.1 5.3
Overton [115] Observed 4 3 8 15
Expected 5.7 4.5 4.7
Telim aa [117] Observed 4 10 3 17
Expected 6.5 5.1 5.3
M ahmood Observed 7 1 3 11
[103]
Expected 4.2 3.3 3.4
Total 23 18 19 60
Chi Sq=14.1
W ith 6 degrees of freedom this gives p=0.029
This still shows significant heterogeneity between the studies but considerably less so 
than when the Harrison study was included. The predominant source of heterogeneity in 
this case is the number of unchanged responses in the Telimaa study.
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A n alternative approach in view of this is to ignore the women who remain unchanged 
and assume that a woman has an equal chance of progressing and regressing. If this were 
the case then p=0.5 (null hypothesis) where as if this were not p*0.5. Using Binomial 
Probability test and using disease regression as the variable the probabilities are shown in 
table 3.4.
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T able  3.4 Binomial Probability test on studies excluding Bergqvist
Study No.
regressing
No.
progressing 
+ regressing
Sample p 95%
Confidence
Intervals
Exact P- 
value
Harrison 27 31 0.871 0.702, 0.964 0.000
[106]
Thomas 5 13 0.385 0.139, 0.684 0.581
[107]
Overton 8 12 0.667 0.349, 0.901 0.388
[115]
Telimaa 3 7 0.429 0.099, 0.816 1.000
[117]
M ahmood 3 10 0.300 0.067, 0.652 0.344
[103]
Combining Thomas, Overton, Telimaa and M ahmood 
19 42 0.452 0.298, 0.613 0.644
The Harrison study has a significantly greater num ber of women regressing than would 
be expected, if the chance of progression and regression are equal. In the other studies 
however, the deviation from a p value of 0.5 is not different than would be expected by 
chance and this rem ains the case even when the figures are com bined (i.e. all the 
confidence intervals straddle 0.5)
Chapter 5 of this thesis is a random ised placebo controlled trial of the COX 2 inhibitor 
valdecoxib for the treatm ent of endometriosis using disease regression as an end point. 
This would thus be eligible for inclusion in this analysis. In the placebo group of this
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study the rAFS scores for each subject are shown in table 3.5. Each subject has an rAFS 
score at baseline, three months and the difference between the two is shown in the last 
column. rAFS scores where assigned by two independent blinded assessors and the mean 
score was calculated for each subject. A sum m ary of those progressing, rem aining 
unchanged and progressing are shown in table 3.6.
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Table 3.5 rAFS score in the placebo group of the Valdecoxib Study (chapter 5)
Baseline rAFS score 12 weeks rAFS score Change
4 4 0
3.5 3 -0.5
10 7.5 -2.5
12.5 9 -3.5
34.5 17 -17.5
6 6 0
4 5 1
8 5 -3
8.5 9.5 -1
1 2.5 1.5
2.5 4 1.5
4.5 5.5 1
0.5 3 2.5
8.5 12 3.5
17 7 -10
10.5 6 -4.5
15 9.5 -5.5
9 5 -4
4 7 3
12.5 7 -5.5
30.5 12.5 -18
T ab le  3 .6  Num bers progressing, unchanged and regressing in placebo group of
valdecoxib study (chapter 5)
Progressed Unchanged Regressed
7/21 2/21 12/21
42
W hen these figures are incorporated  into the previous tests the Chi Sq test of 
heterogeneity are shown in table 3.7
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Table 3.7 Chi Sq analysis including valdecoxib study
Study Progressed Unchanged Regressed Total
Harrison [106] Observed 4 12 27 43
Expected 11.2 12.5 19.2
Thomas [107] Observed 8 4 5 17
Expected 4.4 4.9 7.5
Overton [115] Observed 4 3 8 15
Expected 3.9 4.3 6.
Telim aa [117] Observed 4 10 3 17
Expected 4.4 4.9 7.5
M ahmood Observed 7 1 3 11
[103]
Expected 2.8 3.2 4.9
Current study Observed 7 2 1 21
Expected 5.9 5.4 9.6
Total 34 32 58 103
Chi Sq=32.1 W ith 10 degrees of freedom p=0.000
Again the major heterogeneity is due to the Harrison study. Repeat analysis excluding 
this study is shown in table 3.8
Table 3.8 Chi Sq analysis including valdecoxib study with Harrison excluded
Study Progressed Unchanged Regressed Total
Thomas [107] Observed 8 4 5 17
Expected 6.5 5.1 5.3
Overton [115] Observed 4 3 8 15
Expected 5.7 4.5 4.7
Telim aa [117] Observed 4 10 3 17
Expected 6.5 5.1 5.3
Mahmood Observed 7 1 3 11
[103]
Expected 4.2 3.3 3.4
Current study Observed 7 2 12 21
Expected 8.0 5.1 rj r~j
Total 30 20 31 81
Chi Sq=20.5 W ith 8 degrees of freedom p=0.008
43
The heterogeneity remains but to a slightly less significant level. Again the predominant 
heterogenicity in this case is the unchanged group of the Telimaa study.
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Using the same argument as previously by excluding the unchanged group and assuming 
the same chance of regression as progression (n=0.5), the p values and 95% confidence 
intervals are shown in table 3.9.
Table 3.9 Binomial Probability test including Valdecoxib study
Study No.
regressing
No.
progressing 
+ regressing
Sample p 95%
Confidence
Intervals
Exact P- 
value
Harrison 27 31 0.871 0.702, 0.964 0.000
[106]
Thomas 5 13 0.385 0.139, 0.684 0.581
[107]
Overton 8 12 0.667 0.349, 0.901 0.388
[115]
Telim aa 3 7 0.429 0.099, 0.816 1.000
[117]
M ahmood 3 10 0.300 0.067, 0.652 0.344
[103]
Current 12 19 0.632 0.384, 0.837 0.359
study
Combining Thomas, Overton, Telimaa, M ahmood and current study
31 61 0.508 0.377, 0.638 1.000
Representing this graphically the probability o f regression with 95% confidence intervals 
are shown in figure 3.1
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Figure 3.1 Probability of disease regression with 95% confidence intervals
(a) Harrison (b) Thomas (c) Overton (d) Telim aa (e) Mahmood (f) Current Study 
(g) Thomas, Overton, Telimaa, M ahmood and current study combined
3.4 Discussion
In draw ing any conclusions from  the above data one must be cautious. The overall 
numbers are small and the studies exhibit heterogeneity in both design and results. The 
details of each study have been outlined in chapter 2. There are specific features in the 
m ethodology that are particularly relevant when attempting to draw conclusions from 
them  as a group. There is little difference in the lack o f treatm ent or placebo 
administration between the groups with the exception of the Telim aa study. In this study 
5 o f the 17 patients in the placebo group in fact underwent diathermy to endometriosis at
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the time of the first laparoscopy. At second laparoscopy two of these had regressed and 
two rem ained unchanged. As it is unlikely that diatherm y would have increased the 
likelihood of progression it may be that these would have progressed if left untreated.
All studies used the American Fertility Society scoring system to score disease. However, 
because the studies were undertaken over a period o f thirteen years, some used the 
original AFS scoring system (Thomas and Telimaa) [113] while the others used the more 
modern, revised version [114]. To try and allow for this the actual scores where not used 
in this analysis, only the fact that disease had either progressed, regressed or remained 
unchanged. It is apparent from  review of the scoring system however that there are 
important differences in how points are assigned. In the earlier system, a maximum of 3 
points could be allocated for peritoneal disease with no discrim ination made between 
deep and superficial disease. W ith this m ore lim ited scoring system it is clear that the 
chance of change in numerical score is less than the revised classification which allocated 
a m aximum  of six points for peritoneal disease and did distinguish between deep and 
superficial disease. This may in part explain why relatively few patients in the Telim aa 
study showed change in their AFS score although such effect is not apparent in the 
Thom as study. In the current study, the fact that rAFS score was assigned by two 
assessors and the mean of the two assessments used, does suggest that the chance of no 
change in score is reduced compared with studies using only one reviewer.
The duration of the studies are broadly sim ilar with most having around six months 
between laparoscopies. The exceptions are the valdecoxib study, which at three months is
Natural history of endometriosis
46
rather shorter, and the Mahmood study which is rather longer at one year. There does not 
however appear to be any obvious effect of these variations when looking at the data as a 
whole.
Statistically there is significant heterogeneity between the results of the studies with this 
being the most obvious in relation to the Harrison study. This study, in contrast to the 
other studies, demonstrated a significant increase in disease regression. This study is the 
largest single study and is methodologically good, however, cumulatively the other 
studies have considerably more subjects. One of the commonest reasons for heterogeneity 
between studies is due to differences in the study populations to begin with. Even bearing 
this in mind, it is difficult to identify any consistent differences between the study 
populations, entry criteria and exclusion criteria of the Harrison study compared to the 
other studies. No median age is given for the Harrison study but the range of 20-39 years 
old is around the same as the other studies (all between 19 and 44 years old). No patients 
in Harrison’s placebo group had severe disease in keeping with the other studies and, 
with the exception of Overton study, all included patients with AFS scores up to 39 with 
the vast majority in each case being less than 15. The principle indications for 
laparoscopy in the studies were different with Harrison and Thomas being solely for sub 
fertility, 18 of 19 in the Overton study being for subfertility and 6 of 17 in the Telimaa 
study for sub fertility. The remainder of the patients in Telimaa’s study had pain 
symptoms and the reason for laparoscopy in the Bergquist study was simply stated as 
being for ‘clinical reasons’. All patients in the Valdecoxib study had pain symptoms as 
their primary indication for laparoscopy. Whilst it can be seen that there is some
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heterogeneity in the indication for primary laparoscopy, there is nothing specific about 
the Harrison study, in fact, the fact that fertility was the indication would make it more 
similar to the group as a whole than for example the valdecoxib study. Of those studies in 
whom fertility was the indicator for laparoscopy the duration of infertility does not 
appear to be particularly different between the studies either. Harrison’s population had at 
least 24 months infertility but the median and range is not given. The ranges in the 
Overton and Thomas studies were 18-72 months with a mean of 33.4 and median of 36 
months respectively.
It may be argued that different behaviour of the disease may simply be due to observing 
the disease at different stages of it’s evolution. It may be, for example, that the disease 
progresses for a specific period of time and there after begins to ‘burn out’ and regress. 
As a consequence differences in disease progression may be observed in different studies 
depending on if the entry criteria favour more prolonged disease or not. Duration of sub 
fertility would be a nonsensical surrogate for duration of disease as it is primarily 
dependent on when one begins attempting to conceive. If one commences at 16 years of 
age for example, after two years of infertility it is still unlikely the disease will have been 
present for more than around 7 years at most (average puberty 11 years old). In contrast 
should one not attempt conception until 35 years old and laparoscopy after two years of 
conceptual failure confirmed endometriosis , this may have been present for anything up 
to 24 years. Duration of symptoms may be an acceptable surrogate although, as 
previously mentioned, the condition is often asymptomatic meaning it may have been 
present well before the onset of symptoms. In any case, with exception of infertility, the
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duration of other symptoms are not noted in the included papers making comparison 
impossible. The only other surrogate, for duration of disease is that of age at laparoscopy. 
If one were to assume a very loose link with age in that a younger patient is likely to have 
had the disease for a shorter duration than an older patient, then it is possible trials with 
patients of significant age difference will show differing disease behaviour. In keeping 
with all the other variables however, and as mentioned before, there is no obvious 
difference in the age of the patients in the Harrison study when compared to the other 
studies.
When Harrison’s study is excluded the heterogeneity (whilst still significant) is markedly 
reduced and that that remains is predominantly due to the number of subjects unchanged 
in the Telimaa study, the possible causes of which have been discussed.
By excluding the Harrison study because of it’s contrast to the other studies and by 
ignoring the unchanged subjects in each group because of the Telimaa figures one, can 
cautiously combine the other results to give an impression of the likelihood of 
progression or regression of disease. The results in figure 3.1 of the combined results 
suggest the chance of regressing is not significantly different from progressing. The 
figures are small and as a consequence the confidence intervals are relatively large. 
However based on these confidence intervals it suggests, of those patients whose disease 
changes, the proportion regressing will not be less than 38% nor more than 64%.
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In interpretation of the data it is important to bear in mind that these figures only relate to 
patients included in analysis. Ideally, when conducting any trial, one is aiming to select a 
group of patients that are representative of the population of interest. By their very nature 
patients in randomised controlled trials may not be ‘typical’ of the population as a whole. 
They are likely to be more motivated and compliant and, because of the exclusion criteria 
of the studies, will usually be less ‘complicated’ without confounding variables. Equally, 
they may have been selected because they demonstrate a specific feature of a disease, for 
example sub fertility, and this may not be the only way in which patients with the 
condition present. These factors are particularly important when one is following 
response (subjective or objective) to a treatment. In the case of the subjects in this 
analysis all have had either placebo or no treatment, and the assessments of disease 
change were made objectively (AFS score) by blinded observers. As such, whilst the 
patients included may not be typical of those in the population as a whole, there is 
nothing to suggest that disease progression / regression will be different to that of, for 
example, an unmotivated patient complaining of sub fertility who is unwilling to 
participate in a clinical study.
Clinically at present there is no proven way of predicting those patients in who disease 
progression is likely. Based on these figures, suggesting between 36% and 62% will 
progress, it appears the original statements by Thomas and Mahmood [103, 107] that all 
disease should be treated holds true in the majority of cases. Whilst this will amount to 
over treatment in some cases the consequences of non treatment are significantly worse if 
disease progresses to a stage where either extensive complex surgery is required or
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irretrievable damage has occurred. Exceptions, as outlined in chapter 1 may be patients 
with asymptomatic incidental endometriosis and no future fertility desires.
3.5 Conclusion
From the limited data available in the literature, and in combination with the valdecoxib 
study, a ‘best guess’ as to the natural history of endometriosis is that there is a similar 
chance of progression as regression. With this in mind, and with a few exceptions, it 
would seem appropriate to recommend active treatment of those found to have 
endometriosis.
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Chapter 4 
The Methodology Study
Tlie methodology study
4.1 Introduction
Despite the fact that the rAFS[l 12-114] is used as the standard technique for classifying 
endometriosis it is rather limited in its discriminatory powers when dealing with 
peritoneal disease. By virtue of the fact that it was developed as a scoring system to 
correlate with fertility, points are allocated heavily for disease affecting the fallopian 
tubes and ovaries with very little points being available for peritoneal disease. In fact for 
peritoneal disease alone the highest possible score is 6 which is just into the mild 
category. Thus, if one is specifically interested in change in peritoneal disease, the rAFS 
is a rather blunt tool.
In view of this, I undertook a pilot study to assess the feasibility and reproducibility of 
using digital imaging to assess surface area and numbers of abnormal vessels entering 
specific endometriotic lesions. Similar studies have previously been published using 
digital photography in assessment of melanoma, hypertrophic scars, varicose veins and 
neurodermatitis [164-168].
4.2 Hypothesis
The hypothesis was that the use of digital photograph in combination with computer 
analysis would provide a reproducible method of quantifying surface area of 
endometriotic lesions and numbers of abnormal vessels entering endometriotic lesions.
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Subjects
This was a three centre study with multicentre research ethics committee (MREC) 
approval. Six patients were recruited (two from each site). Inclusion criteria were patients 
who were due to undergo a laparoscopy for suspected or known endometriosis, were over 
eighteen years old, had all gynaecological organs present and had given informed 
consent. There was no limitation on stage of disease for inclusion.
Image capture
All patients underwent laparoscopy after menstruation had ceased and before 14 days 
prior to the next expected menstruation based on their normal cycles. Thus it was ensured 
they were in the proliferative phase of the cycle. Laparoscopic entry was carried out in 
the usual way as per the practice of the gynaecologist, with particular care being taken 
when the uterus was instrumented not to be too vigorous with the bimanual examination. 
On entry the abdominopelvic cavity was inspected in the usual way at which time an 
endometriotic ‘index’ lesion was selected. This was a lesion that was anatomically 
relatively easy to photograph with no / minimal manipulation needed, next to which 
could be placed a needle. The operating camera system was then detached from the 
laparoscope and replaced by a Nikon ‘COOLPIX 4500’ digital camera with a special 
adaptor to allow attachment of the camera to the end of the laparoscope.
4.3 Method
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The camera set up
A straight 13mm surgical needle (with 2.0 vicryl attached) was introduced via a second 
port and placed as close to the lesion as possible in the same plane. The settings on the 
camera system were as follows:
• Memory bank - 1
• Flash off
• White balance - Incandescent
• Sensitivity - 400
• Metering -  Centre Weighted
• Image Adjustment -  Normal
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• Image Quality -  Fine
• Exposure mode -  Auto
• Shutter speed -  1/60
• Aperture size -  F5.1
• Number of exposures remaining -  4
Using auto focus, supplemented by manual focus where necessary, the lesion was 
photographed close up ensuring the whole lesion and needle was in view. The 
laparoscope was then pulled back, camera refocused, and a wide angle picture taken to 
allow location of the lesion to be demonstrated.
Close up image of lesion
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Wide angled view of lesion
The laparoscope and needle were then removed and the camera system detached. 
Following this the whole process was then repeated to obtain a second set of images. The 
remainder of the laparoscopy was completed by the laser ablation of all visible 
endometriosis and the closure of the abdominal port sites by the usual practice of the 
operating gynaecologist.
Images captured on the digital flash card were then downloaded on to the hard drive of a 
Compaq Evo computer and copies of each pair (close up and wide angle) of images were 
stored on individual compact discs.
57
The images were analysed independently by two gynaecologists using a specifically 
prepared software package produced by Virtualscopics, Rochester, New York State, 
USA. The twelve individual close up images were presented in random order for each 
assessor to quantify. The original intent was to quantify the surface area of each lesion 
and the number of vessels entering, however on review of the image, quantitative vessel 
analysis was not possible due to both the quality of the images and the size and 
irregularity of the vessels. The surface area was calculated by first defining the needle for 
scale. The individual components of each lesion, red, black and white (as defined by the 
rAFS definition) were then circumscribed by the investigators using any combination of 
the various functions. Functions available were;
Filters
Red, Green, Blue, Black and White 
Delineators
Live Wire Mode: Allows you to optimize the path drawn between successively user 
defined points.
Shrink-Wrap Mode: Allows you to define a structure by roughly tracing the outside 
perimeter of a well defined structure.
Region Growth Mode: Allows you to identify, with one mouse click, an entire well 
defined structure.
3-D Region Growth Mode: Similar to the Region Growth Mode, but the growth will 
proceed in three dimensions
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Geometrically Constrained Region Growth (GEORG) Mode: Allows you to define 
the shape of the geometric model. The model is used to smooth region boundaries and 
limit growth outside a structure of interest.
3-D GEORG Mode: Operates on the same principle as GEORG, with the additional 
functionality of growth proceeding in three dimensions.
Add Mode: Allows you to use free hand tracking to modify a currently finalized (red) 
contour by adding a new area.
Adjust Mode: The Adjust Mode allows you to modify the active contour. Each time the 
left mouse button is clicked, the contour is forced to pass through the clicked point. 
Continuous Trace Mode: Allows you to perform free hand tracing of structure 
boundaries.
Erase Mode: Allows you to modify the currently finalized contour by using free hand 
tracing to delete the unwanted portion of the region.
Polygon Mode: Allows you to manually trace structure boundaries by connecting points 
that the user made in the Image window. Straight lines are used to connect points defined 
by successive mouse dicks.
Rectangle Mode: Allows you to define a rectangle.
Select Mode: Allows you to convert a finalized (red) contour to an active (blue) contour.
When the investigator was happy with the defined area the image was finalised and the 
computer calculated the surface area using the needle as a reference.
The methodology study
59
The methodology study
Lesions after borders have been delineated by assessor for computer analysis
Statistical analysis
Assessment of reproducibility was made both between the two lesions when assessed by 
each individual assessor and comparison between assessors. The intra observer 
reproducibility was assessed by a combination of variance, coefficient of variation and by 
visual inspection of plots of the surface area calculations. Inter observer variability was 
assessed by inspection of plots of the surface area calculations.
4.4 Results
The total lesion area and breakdown of red, black and white components as assessed by 
the two assessors are shown in tables 4.1 and 4.2
60
The methodology study
T ab le  4.1 Assessor 1 Surface area o f each lesion
Subject Site Image
Total Red
Lesion Area (mm2) 
Black White SubjectMean
Centre
Mean
1
1
Portsmouth
Portsmouth
A
B
0.54
0.53
0.54
0.53
0
0
0
0
0.54
1.32
2
2
Portsmouth
Portsmouth
A
B
2.01
2.18
2.01
2.18
0
0
0
0
2.10
3
3
4 
4
Kingston
Kingston
Kingston
Kingston
A
B
A
B
68.94 
66.52 
19.13
27.94
25.72
26.11
1.75
2.29
9.03
10.21
0.25
0.65
34.19
30.2
17.13
25
67.73
23.54
45.63
5
5
6 
6
Guildford
Guildford
Guildford
Guildford
A
B
A
B
14.38
14.19
33.09
27.49
14.38
14.19
12.5
9.68
0
0
1.78
1.56
0
0
18.81
16.25
14.29
30.29
22.29
Table 4.2 Assessor 2 Surface area of each lesion
Subject Site Image
Total Red
Lesion Area (mm2) 
Black White SubjectMean
Centre
Mean
1
1
2
2
Portsmouth
Portsmouth
Portsmouth
Portsmouth
A
B
A
B
0.48
0.62
3.74
7.32
0.48
0.62
3.74
7.32
0
0
0
0
0
0
0
0
0.55
5.53
3.04
3
3
4 
4
Kingston
Kingston
Kingston
Kingston
A
B
A
B
15.57
19.1
17.94
34.79
9.6
10.68
0.91
1.47
5.97
8.42
0.6
1.28
0
0
16.43
32.04
17.34
26.37
21.85
5
5
6 
6
Guildford
Guildford
Guildford
Guildford
A
B
A
B
11.4
11.85
35.43
19.01
7.3 
8.91
8.03 
6.65
0
0
1.19
1.55
4.1
2.94
26.21
10.81
11.63
27.22
19.42
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The range of the size of the index lesions selected for assessment is wide (0.5mm2 to 
69mm2). The Portsmouth site selected smaller lesions than the other two sites.
The index lesions for three of the six subjects as assessed by assessor 1 and two of the six 
as assessed by assessor 2, contained only red tissue and had no black or white 
component. These were also the three smallest lesions.
Plots of the lesion areas for the duplicate assessments made on each subject are presented 
in figures 4.1-4.12 (by subject) and in figures 4.13-4.20 (by area type).
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Fig 4.1 Assessor 1
Subject 1 (Portsmouth)Assessor 1
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Fig 4.2 Assessor 2
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Fig 4.3 Assessor 1
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Fig 4.5 Assessor 1
Fig  4.6 Assessor 2
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Fig 4.7 Assessor 1
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Fig 4.9 Assessor 1
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Fig 4.11 Assessor 1
Subject 6 (Guildford)Asessor 1
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F ig  4.13 Assessor 1
Total Lesion Area
Fig 4.14 Assessor 2
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F ig  4.19 Assessor 1
White Lesion Area
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The within and between subject variance components of the index lesion assessments are 
shown in tables 4.3 and 4.4, and the with-in subject coefficient of variation (sd/mean) is 
shown in tables 4.5 and 4.6.
T able  4.3 Assessor 1 Variance
Lesion Area Between - 
Subject 
Variance 
Component
Within-Subject
Variance
Component
Total
Variance
% Variance
Between
Subjects
% Variance
Within
Subjects
Total 609.58 9.57 619.15 98.5 2.5
Red 96.82 0.71 97.53 99.3 0.7
Black 14.45 0.13 14.58 99.1 0.9
White 186.95 7.03 193.98 96.4 3.6
T able 4.4 Assessor 2 Variance
Lesion Area Between - 
Subject 
Variance 
Component
Within-Subject
Variance
Component
Total
Variance
% Variance
Between
Subjects
% Variance
Within
Subjects
Total 94.6 48.3 142.9 66 34
Red 14.17 1.57 15.74 90 10
Black 7.62 0.55 8.17 93.3 6.7
White 97.03 40.18 137.21 70.7 29.3
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T ab le  4.5 Assessor 1 C oeffic ien t o f V aria tion  (C V )
Lesion Area Overall Mean CV (Total) CV (Within Subject)
Total 23.08 107.8 13.4
Red 9.32 106.0 9.0
Black 1.96 194.8 18.4
White 11.80 118.0 22.5
T able  4.6 Assessor 2 Coefficient of Variation (CV)
Lesion Area Overall Mean CV (Total) CV (Within Subject)
Total 14.77 80.93 47.1
Red 5.48 72.4 22.9
Black 1.58 180.9 46.9
White 7.71 151.9 82.2
Discussion
The range of both lesion size and lesion components in these patients is quite wide with 
som e small lesions having only red com ponents and other larger lesions being 
predominated by white areas.
In assessing reproducibility of a test there is no standard single ‘test’ that can be applied 
to give a quantitative assessm ent of reproducibility. In this experim ent we used the 
coefficient of variation (CV) how ever this should be interpreted with caution as the 
num ber of assessm ents is small and as such will be m arkedly influenced by any 
‘outlying’ variables. As a general rule a CV of 100 is used as the cut off for acceptable 
lack of variation, but clearly the figure is a continuum with the lower the figure the less 
the degree of variability. The C V ’s obtained in this study for both assessors show good
74
reproducibility for within-subject analysis with all figures being below 100. Variability in 
all cases was less in assessor one than assessor two, with the within-subject variation 
contributing between only 0.7% and 3.6% of the total variance of assessor 1 compared to 
a within-subject variance in assessor 2 of between 6.7% and 34%. It is important to note 
however that, by the fact that the percentage variance figures given in tables 4.3 and 4.4 
are percentages, then the figures are proportions. Thus if, as in the case of assessor 1, the 
betw een-subject variance com ponent is high, then proportionately, and thus as a 
percentage, the within subject variance will be low. This can therefore give an artificial 
impression of a smaller within-subject variance than is actually the case. Looking at the 
true figures of variance it is still clear assessor 1 had consistently less within-subject 
variability  than assessor 2, although to a lesser extent than is apparent from  the 
percentage figures.
On review of the techniques used by both assessors, assessor 1 used significantly more 
m anual tracing of the regions using the live wire m ode than assessor 2, who 
predominantly used the more autom ated functions of regional growth and geometrically 
constrained regional grow th m odes. This w ould im ply that although m ore tim e 
consum ing, semi autom ated manual draw ing of the lesions is a m ore reproducible 
technique.
In both cases the m ost reproducible com ponent o f analysis was the red area. This is 
encouraging as red areas are considered most active [169] and thus if one were to test any
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new treatm ent of active endometriosis, one would expect these areas to respond first and 
possibly to a greater extent.
The total CV for the two assessors are clearly far less reproducible. As a function of both 
between subject variance and within subject variance this would be expected due to the 
wide range of lesion sizes and compositions. In assessing efficacy of any treatment (or 
indeed sim ple change in disease) one is interested in change in individual lesions or 
components of individual lesions and not change in total areas of lesions in a combined 
set of patients. As such this variation is unimportant.
A more valid way of assessing the reproducibility of a test is to include both qualitative 
and quantitative figures. Thus the plots o f lesion size are equally important in drawing 
conclusions on reproducibility and also allow us to assess inter observer variability. The 
intra observer variability is dem onstrated m ost clearly on figures 4 .13-4.20 where 
individual assessors’ area calculations are shown for each com ponent of the pairs of 
lesions. Inter observer variability can be assessed by reviewing all the figures presented. 
From figures 4.13-4.20 the intra observer reproducibility of the red and black areas 
appears very good in both observers. It does need to be rem em bered however that 
assessor 1 found no black areas in three of the subjects and assessor 2 found no black 
areas in two subjects thereby making the plots of the black areas for the six subjects look 
better than perhaps is truly the case. Red areas however were present in all subjects and 
the reproducibility is good through out. The total lesion areas and white lesion areas do 
seem to show greater variability with the greatest variability being apparent in the larger
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lesions. The reduced reproducibility of these areas compared to the red and black areas 
probably relate to the fact that the red and black areas have more obvious borders and 
thus confines. We are looking at lesions on a background of peritoneum which itself has a 
white / greyish appearance. As such, to identify a border betw een a white area of 
endometriosis and normal peritoneum  is considerably harder, and hence more prone to 
error, than defining a border between a red or black area and normal peritoneum. The 
greater variability seen in the larger lesions is most likely to be as a consequence of size. 
The potential for error is going to increase the greater the lesion size as the border to be 
defined is longer. In addition the plots show actual lesion size rather than relative 
differences between plots. Thus, a 20% difference in actual surface area between plots in 
a small lesion will be m arkedly sm aller than a 20% difference in a larger lesion. In 
reviewing plots of the two assessments the larger lesion will have a much steeper slope 
between the two plots than the smaller lesion despite the relative difference in the two 
assessments being the same.
From all plots it is clear that the reproducibility of analysis is significantly worse between 
assessors. The differences between the assessors when assessing the black areas does not 
seem great however, as previously mentioned, this is because no black areas were present 
in two of the subjects (as assessed by both assessors) and, with the exception of subject 3, 
the black areas in the other subjects where very small. The lesion from subject 3 showed 
wide variation in all areas of assessment between the two assessors. On review this lesion 
(shown in fig 4.21) is a very complex lesion making potential for error great.
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Fig 4.21 Com plex lesion from  subject 3
There w as no consisten t d ifferences betw een  the assessors how ever, it is interesting to 
note that w hilst the red area w as m ost reproducible, w ithin observer analysis w as in fact 
the area that show ed m ost variation betw een  observers. Thus it w ould  appear, although  
borders o f  these areas are easier than other areas to elucidate, the subjective decision  as to  
w hether an area is red, black or w hite still rem ains to be made by the assessor and this 
appears to show  more variability.
W hen assessin g  reproducibility one m ust be aware o f  the com ponents contributing to the 
variability. The tables and figures concentrate on the variability w ithin and betw een the
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two assessors. In fact the pairs of lesions analysed in each case are not the same image of 
the lesion but two different images of the same lesion taken at different times (albeit the 
same operation). Thus the within-subject variation is not only a function of the variability 
of the assessor, but also the variability of the image taken. Whilst efforts are made to 
minimise variability in images, inevitably the photograph will not be taken at exactly the 
same angle, the needle will not be in exactly the same position and other variables will be 
slightly different. These differences are important to be aware of as they are likely to be 
minimized in this study by the fact that the images where captured at the same operation 
a short duration apart. In studies assessing efficacy of a treatment over time images will 
be captured at separate operations, some time apart, there by almost certainly increasing 
these variables.
The aim of development of new analysis techniques is to allow detection of clinically 
significant effects of a treatment on a disease, in this case to detect a clinically significant 
difference in endometriotic lesions. In endometriosis, whilst one can make assumptions 
as to what would be a clinically significant reduction in pain for example, because of the 
lack of correlation of symptoms with disease it is not possible to logically select a figure 
for clinically significant change in lesion surface area (with the exception of total disease 
irradiation). What is important, however, is to be aware of the ability, or limitations, of a 
test to detect a difference. A test that has a relatively high variability is going to be unable 
to detect small differences between two groups as the difference will be ‘masked’ by the 
background intrinsic variability. From the results using this technique assessor 1 should 
be able to detect a between-subject variance of more than 3.6% and assessor 2 a between-
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subject variance of more than 34%. These figures should be born in mind when 
interpreting the results.
4.6 C onclusion
This technique demonstrates acceptable intra observer variability for both assessors 
however there is significant operator dependence in reproducibility. The intra observer 
reproducibility is relatively poor. In using this technique to evaluate disease change one 
should use intra observer analysis, preferably with an assessor with a low intra observer 
variability.
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Chapter 5 
The Valdecoxib Study
The valdecoxib study
As described in chapter 1, COX 2 appears to have a role in the both the angiogenic 
potential of endom etriotic lesions and the local production of oestrogens within the 
lesions. It could be hypothesised therefore that inhibition of COX 2 could cause 
regression of endometriosis by interrupting these two mechanisms. The potent angiogenic 
factor VEGF, one of the main products of COX 2, should be reduced. Additionally, PGEj 
another substance with m arked angiogenic potential should also be reduced as its 
production was inhibited in COX 2 knockout fibroblasts [90]. Because of the need of 
implants to stimulate angiogenesis to survive and grow, inhibition of two of the main 
factors responsible for this should cause lesions to regress.
Arom atase is responsible for the production of locally raised oestrogen concentrations 
w ithin endom etriotic lesions [93, 170] which then potentiates the growth of this 
oestrogen dependent tissue. The reduced production o f PGEj should mean there is less 
induction of aromatase and thereby less local conversion of the androgens androstendione 
and testosterone to oestrone and oestradiol. A dditionally, the relative reduction in 
oestrogens will reduce their positive feedback on COX 2 to produce PG E2 and therefore 
interrupt the positive feedback loop that exists. Inhibition of COX 2 therefore should 
reduce the local oestrogen concentration and in part the ‘driving fo rce’ for continued 
growth of the lesion.
5.1 Introduction
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Based on this rationale, a study was conducted to test the hypothesis that the use o f 
valdecoxib (a COX 2 inhibitor) will cause regression of active peritoneal endometriosis 
over a  three m onth period.
5.2 M eth o d
Study Design
A  random ised, double blind, placebo controlled trial was conducted in four hospitals in 
the U K  to evaluate the efficacy o f 40m g daily o f valdecoxib in causing regression of 
endom etriosis over a  tw elve w eek period (See appendix 4  fo r dosage inform ation). 
T w enty patients were allocated to each arm  (placebo and valdecoxib treatm ent). The 
study was instigated by Pfizer U K , w ho funded the project. T he study design was 
developed by both Pfizer and the study investigators and all recruitm ent, patient contact 
and surgery w as perform ed by the on site investigators. A ll d isease analysis was 
perform ed by Professor C Sutton, M r A  K ent and M r T Carpenter o f the Royal Surrey 
C ounty  H ospita l. A pproval w as ob tained  from  the M ulti-centre  R esearch  E thics 
Com m ittee as well as the Local Regional Ethics com m ittee in each hospital.
Prim ary end points were change in severity o f endom etriosis as assessed by revised 
A m erican Fertility Society scores and change in size of an ‘index’ lesion. Secondary 
outcom es were pain as assessed by visual analogue scales (com pleted w eekly in the 
patien t d iary  and during  v isits 2 ,4  and 5), quality  o f life and effect on sexual 
relationships as assessed by Endom etriosis H ealth Profile Q uestionnaire 30 (EHP-30) 
and peritoneal fluid V ascular Endothelial Growth Factor concentration.
The valdecoxib study
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Women were recruited from waiting lists and directly from gynaecological outpatient 
departments. All had symptoms and / or signs suggestive of endometriosis for which a 
laparoscopy was recommended. Patients were given detailed patient information sheets 
and, if they wished to be considered, were invited for a screening visit (VI). Details of 
each visit are outlined later. Inclusion criteria for subjects at the screening visit were;
1. 18 years old or older
2. Negative pregnancy test, not breast feeding and prepared to use a non hormonal 
contraceptive for the duration of the study
3. Clinical suspicion of endometriosis (dysmenorrhoea., dyspareunia, pelvic pain) 
requiring a laparoscopy for diagnostic and / or therapeutic purposes
4. Intact uterus and ovaries and menstruating
5. No treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or 
cyclooxygenase 2 inhibitors within one menstrual cycle prior to randomisation
6. No treatment with NSAIDs or coxibs after screening visit
7. No pharmacological treatment for endometriosis three months prior to the 
screening visit with the exception of simple analgesics. This includes oral 
contraceptives
8. Evidence of a personally signed and dated informed consent form indicating that 
the subject has been informed of all pertinent aspects of the trial
9. Subjects are willing and able to comply with the scheduled visits, treatment plan, 
laboratory tests and other study procedures.
Subjects
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1. Concomitant therapy with other investigational drugs
2. Regular (one dose or more per week) treatm ent with NSAIDs or coxibs prior to 
the one menstrual cycle before random isation. No NSAIDs or coxibs allowed 
within one menstrual cycle prior to random isation and no NSAIDs or coxibs 
allowed after screening visit. Occasional PRN use before this time is allowed
3. Requirement to use other medication during the study that may interfere with the 
evaluation of the study drug
4. Current condition of abdominal pain which, in the opinion of the investigators, 
may confound study assessments, such as irritable bowel syndrome.
5. Known sensitivity to NSAIDs, coxibs or lactulose
6. A ctive  o r suspected  oesophagea l, gastric , or duodenal u lceration  or 
gastrointestinal bleeding w ithin 30 days of receiving the first dose of study 
medication
7. Inflam m atory bowel disease, acute or chronic renal or hepatic disorders, a 
significant coagulation defect, or any condition which in the investigators’ 
opinion might preclude the use of a NSAID e.g. congestive cardiac failure
8. Active malignancy or history of malignancy. Patients with a history of basal cell 
carcinom a that has been successfully treated are acceptable. Patients with a 
history of other malignancies which have been surgically rem oved and have no 
evidence of recurrence for at least five years before enrolment into the study are 
also acceptable.
Exclusion crite ria  at the screening v is it were;
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9. Unable and / or unlike to com prehend and follow the study protocol
10. Alcohol and/or other drug abuse
11. Known laboratory abnorm alities which, in the opinion of the investigator, would 
contraindicate study participation including AST, ALT, creatinine or urea m ore 
than 1.5 times the upper lim it o f the normal range
12. D onation o f blood or blood products fo r transfusion w ithin four weeks o f the 
initiation o f study m edication or at any tim e during the study
13. O ther severe acute or chronic m edical or psychiatric conditions or laboratory 
abnorm ality  that m ay increase the risk associated w ith study participation or 
study drug adm inistration, or m ay interfere with interpretation o f study results 
and, in the opinion o f the investigator would m ake the subject inappropriate for 
entry into the study.
If  these criteria  w ere m et, subjects subsequently  attended fo r v isit tw o at w hich a 
laparoscopy was undertaken. A t laparoscopy only, subjects with a  confirm ed diagnosis 
of peritoneal endom etriosis o f rAFS grades 1 or 2 were eligible for random isation into 
active treatm ent or placebo groups. Patients w ith any other pathology, endom etriosis 
m ore severe than rAFS grade 2 or in whom  no pathology was found w ere excluded 
from  the study at this point. Those with m oderate or severe endom etriosis or with other 
pathology were treated at this laparoscopy.
Study visits
A n overview  of procedures undertaken during each visit are shown in table 5.1 (Pg 96).
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Visit 1(V1) was carried out within four weeks of the first laparoscopy (V2). A t this visit 
basic dem ographic data was collected along with a detailed medical history including 
date of first diagnosis o f endom etriosis (if diagnosis made previously), any previous 
medical and surgical treatments of endometriosis and any current medication being taken. 
A  general physical examination was undertaken including recording of vital signs (pulse, 
blood pressure and temperature) as well as a gynaecological examination. If due within 
the NHS screening programme, a cervical smear was taken. All inclusion and exclusion 
criteria were checked and informed consent obtained. Blood samples were taken at this 
visit and analysed for full blood count, urea, creatinine and electrolytes, liver function 
tests including lactate dehydrogenase (LDH). A sample of urine was tested using 
M ultistix 8 SG (Bayer) dip sticks and if there was any suspicion of infection from this a 
form al mid stream urine sample was sent for m icrobiological culture and sensitivity 
testing. A urinary pregnancy test was also undertaken. A provisional date was then given 
for the second visit corresponding to the proliferative phase of the next (or possibly 
current) menstrual cycle. If the date of the next menstrual period varied unexpectedly the 
date for visit two was moved accordingly.
A t visit two (V2), prior to laparoscopy, the vital signs and date of the last menstrual 
period were recorded as well as a urinary pregnancy test being undertaken. Assessment of 
pre treatm ent symptoms were made using two tools. Pain was assessed using a 10cm 
visual analogue scale for dysmenorrhoea, non-menstrual pelvic pain and dyspareunia 
over the preceding four w eeks appendix 1. Q uality of life and effect on sexual 
relationships were assessed using the Endometriosis Health Profile Questionnaire (EHP-
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30) appendix 2. Patients then underwent laparoscopy. Laparoscopic entry was undertaken 
in the usual manner of the operating gynaecologist. A bimanual examination was avoided 
however prior to instrumentation of the uterus to prevent possible petechial haemorrhages 
of the pelvic peritoneum that may be confused with endometriosis. Once laparoscopic 
access was obtained a brief inspection o f the abdominopelvic cavity was undertaken to 
assess if the inclusion criteria for random isation were met. Care was taken during this 
process to ensure m anipulation of the viscera was atraum atic to prevent peritoneal 
petechial haem orrhages. If eligible for entry into the trial, a detailed survey of the 
abdominopelvic cavity was undertaken in a systematic way beginning in the right upper 
quadrant and moving in an anti clockwise direction down to the pelvis and then on to the 
left upper quadrant. Care was taken to demonstrate all disease and adhesions. This survey 
was recorded on either digital cassette  (G uildford), VHS cassette  (Portsm outh, 
Southampton) or Super VHS cassette (Chertsey) to allow scoring by blinded assessors at 
the end of the study. A n endometriotic lesion was then selected that met the criteria set 
out in the m ethodology study outlined earlier. In addition the lesion had to be in a 
location to allow safe biopsy at the second laparoscopy. The lesion, named the index 
lesion, was then photographed as per the technique used in the methodology study. In 
addition to the wide angle picture, details of location of the index lesion were recorded in 
the patients notes.
A sample of peritoneal fluid was then taken from the pelvis for later analysis of vascular 
endothelial growth factor (VEGF). This was transfered to a -78°C  freezer within five
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minutes where it was stored until analysis. No surgical treatment was undertaken and the 
laparoscopy was then concluded in the normal way.
Patients not meeting the inclusion criteria for randomisation did not undergo any of the 
above procedures at laparoscopy how ever any treatm ent deem ed necessary was 
undertaken at that time.
Random isation to active drug (20mg valdecoxib twice daily) or placebo was done in 
order o f enrolm ent at each site. Using a com puter generated random isation schedule 
prepared prior to the start of the study at Pharmacia laboratories, active drug or placebo 
were packaged, num bered and sent to each site. All tablets and packaging appeared 
identical and they were dispensed in num erical order to the patients in order of 
randomisation. The randomisation ratio was 1:1 valdecoxib : placebo.
Prior to discharge the patients were given;
1. Postoperative analgesia -  cocodamol 30/500 (24 tablets) for 3 days
2. Patient Study Diary
3. Rescue medication for standard pain re lief- cocodamol 8/500 (60 tablets)
4. Study medication -  two pots of 90 tablets
5. Appointments for subsequent visits
6. Direct contact telephone numbers for study investigators
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The postoperative analgesia was as per standard procedure for post operative pain relief 
and patients were instructed that they could use it on a PRN basis until the end of day 
three. There was no requirement to enter this into the study diary.
In the study diary subjects were required to record all rescue medication taken, any other 
medication taken, any adverse events and com plete weekly visual analogue scales for 
dysm enorrhoea, non menstrual pelvic pain and dyspareunia for the preceding week, 
beginning one week after the laparoscopy. Patients were rem inded to use rescue 
m edication provided and / or paracetomal for pain relief as required and to avoid NSAIDs 
and coxibs. They were also given a list of all over the counter preparations that contained 
NSAIDs and were to be avoided.
They were advised to begin the study m edication within 72 hours of the laparoscopy and 
record date and time of com m encem ent in their diary, and thereafter to take the study 
drug twice daily with food for the duration of the study.
All digital photographs were downloaded on site and copied onto two compact discs. One 
was retained at site and the other sent to Kendle international data m anagem ent for 
storage. All video recordings were sent to the Guildford site where a copy was made. The 
original was then sent to Kendle international data management for storage and the copy 
returned to site.
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Visit three (V3) was two weeks +/- 2 days after visit two. The study diary was checked 
and all rescue medication, other medication, visual analogue scales, any adverse events, 
last menstrual period and num ber of study drug tablets remaining recorded. A urinary 
pregnancy test was undertaken.
Visit four (V4) was six weeks +/- 2 days after visit two. The study diary was checked and 
all rescue medication, other medication, visual analogue scales, any adverse events, last 
menstrual period and number of study drug tablets remaining recorded. In addition visual 
analogue scales were completed by the patient for dysmenorrhoea, non-menstrual pelvic 
pain and dyspareunia in the four weeks preceding this visit. A urinary pregnancy test was 
again undertaken.
Visit five (V5) was undertaken 12 weeks +/- 5 days after V2. All remaining data from the 
study diary was recorded including rescue medication, other medication, visual analogue 
scales and any adverse events and the diary was retained. The date of taking the last dose 
of study medication was recorded as well as the last menstrual period. Study medication 
was counted and returned to pharmacy. The patient then completed a further EHP-30 
questionnaire and visual analogue scales assessing dysmenorrhoea, non-menstrual pelvic 
pain and dyspareunia over the preceding four weeks. Blood samples were taken for full 
blood count, urea, creatinine and electrolytes and liver function tests including LDH.
The laparoscopy undertaken during this visit was carried out in an identical m anner to 
that of V2 with videoing of the abdominopelvie cavity, photography of the index lesion
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and sampling of the peritoneal fluid. Additionally, the index lesion was then biopsied and 
transferred to formalin for storage prior to histological examination. The remainder o f the 
procedure was completed in the usual way as per the operating gynaecologist with the 
ablation or excision of any remaining endometriosis.
Digital photographs and video recordings were copied and handled in the same way as in 
visit two. Biopsies of the index lesions were sent for storage to Pfizer laboratories within 
72 hours.
Analysis
Digital photography analysis
All close up images had identifiable data such as file names rem oved and replaced by 
random numbers by Kendle data management. These images were then stored at Pfizer 
UK, for analysis using the com puter program me described in the m ethodology study 
(chapter 4). Analysis was undertaken by one assessor (TC) over a one week period. This 
assessor had previously undertaken image analysis in the methodology study and been 
shown to have low intra observational variation
Revised American Fertility Society Score (rAFS score)
Video tapes had all identifiable data rem oved and replaced by random  numbers by 
Kendle data management. These were then viewed independently by two assessors (CS 
and TC) and a rAFS score assigned to each. The mean score for each patient was then 
calculated and used for analysis.
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Peritoneal flu id  V EG F concentration  was analysed using the B iotrak  V ascular 
Endothelial Growth Factor, Human ELISA System (Amersham Biosciences, 2003).
Statistics
As no study had been published assessing effect of COX-2 inhibitors on endometriotic 
lesions a power calculation using disease regression as a primary end point was not 
possible. W hilst one could set the acceptable level of type I error at 5% (ie. finding a 
significant difference and rejecting the null hypothesis when in fact the null hypothesis is 
true), to choose an acceptable type II error (ie. finding a non significant result when the 
null hypothesis is not true) one needs to have some idea of the size of the effect one is 
interested in or expecting. No logical figure can be placed on this as there are no previous 
studies to suggest the size of the expected difference and one cannot, with any logic, pick 
a figure for reduction in rAFS score that is clinically m eaningful. In addition, to 
determine a sample size that has a specific power to determine a particular difference one 
needs to know the expected variance in the predicted figures. W ith no previous studies 
such information does not exist. The sample size of 40 was thus chosen largely on the 
basis of practicality and results would guide power calculations for further larger studies 
if required.
M ore information was available in the literature on the effect of endometriosis on pain 
scores, a secondary end point in this study. Miller[ 172] performed a four week controlled
Peritoneal Fluid V E G F
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study o f a gonadotrophin releasing horm one agonist versus placebo in endometriosis 
pain. Pain was assessed using a 10 point visual analogue scale separately for 
dysm enorrhoea, dyspareunia and non-m enstrual pain. The standard deviation of the 
com bined VAS score was around 3.5 w ith a mean score of 9.5 at week four for the 
placebo group. Assum ing a standard deviation of 3.5 for the combined VAS score at 
week 12 in this study, then 20 patients in each arm would provide the following power to 
detect the specified between group differences at a two-sided significance level of 5%.
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D ifference in  com bined VAS score Pow er (%)
3.5 86
3.0 75
2.5 59
2.0 42
Since, in this study, statistical analysis will compare the treatment with regard to change 
in scores (week 12 minus baseline), with baseline fitted as a covariate, these estimates of 
power were thought most likely to be conservative.
All efficacy analysis was performed on the intention to treat or full analysis set (FAS) 
and per protocol set (PPS) cohort. Patients were included in the PPS cohort if all the 
inclusion criteria were met and none of the exclusion criteria, and had no major protocol 
violations during the study. The PPS set were identified before unblinding the study.
The primary method of statistical analysis was by analysis of covariance (ANCOVA) 
whereby the treatments were compared with regard to change from baseline to week 12 
for each variable with baseline included in the model as a covariate. A last observation
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carried forw ard approach was used for subjects who withdrew prior to the week 12 
evaluation.
The three VAS scores (dysmenorrhoea, non-menstrual pelvic pain and dyspareunia) were 
analysed separately and as a combined total.
Data found to depart from the normal distribution was analysed using Hodges-Lehmann 
or W ilc o x o n  R an k  Sum  te s ts  and  / o r ran k ed  A N O V A  in s te a d .
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T a b le  5.1 Sum m ary o f study v is its
Protocol 
activities 
and forms 
completed
Visit 1 
(Approx -2  
weeks)
Visit 2 
(week 0)
Visits 3 and 4 
(weeks 2 and 6)
Visit 5 
(week 12)
Screening 
clinic visit
Laparoscopy
1
Clinic visits Laparoscopy 2
Eligibility
Medical & 
Gynae. history 
& examination
X
Check inclusion 
& exclusion 
criteria for 
screening
X
Check inclusion 
& exclusion 
criteria for 
randomisation
X
Consent X
Safetv
Medical & 
Gynae. history 
& examination
X
Vital signs X X
Cheek for 
adverse events
X X X
Check for
concomitant
medication
X X X X
Laboratory tests X X X
Urinary 
Pregnancy test
X X X X X
Evaluation
Laparoscopic
assessment
X X
Sample
peritoneal fluid
X X
Biopsy
endometriotic
lesion
X
VAS scores X X X
EHP-30 QOL 
questionnaire
X X
Record rescue 
medication
X X X
Supplies
Randomisation 
& dispense 
study
medication
X
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V isit 1- the screening v isit (V I) was carried  out prior to random isation at V isit 2. 
Because of this three patients had com pleted V 1 and were awaiting V 2 at the stage that 
40 patients had been random ised. These patients were allowed to continue in the study. 
43 patients were random ised, 22 to the valdecoxib group and 21 to placebo. Baseline 
dem ographics and rAFS scores for the two groups were sim ilar and are shown in tables
5 .2  and 5.3. B ecause rAFS scoring  w as perform ed by b linded  assessors at the 
com pletion of the study, there was som e discrepancy in the rAFS stage allocated to 
subjects . In five subjects the assessors scored the patients as m ore than stage 2 disease 
w hich the on site investigators had calculated as stage 2 disease. These are included in 
the full set analysis.
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Subjects and baseline demographics
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T ab le  5.2 Demographic Characteristics
Valdecoxib Placebo
Number of Subjects 22 21
Age (years):
18-24 9 5
25-29 5 7
30-34 5 3
35-39 3 4
40-44 0 1
45-50 0 1
Mean 27.0 29.9
SD 6.1 7.4
Range 19-39 18-46
Race:
W HITE 22 19
BLACK 0 1
ASIAN 0 1
W eight (kg):
M ean 64.1 63.8
SD 11.5 10.9
Range 49.0-98.0 43.8-81.6
N 22 21
Body Mass Index:
M ean 23.8 24.4
SD 4.1 3.6
Range 18.5-34.5 17.9-31.1
N 22 21
Height (cm):
M ean 164.1 161.3
SD 6.0 5.2
Range 154.0-175.0 152.0-170.0
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T ab le  5.3 Baseline rAFS scores
rAFS stage Valdecoxib 20mg bd 
N=22*
Placebo
N=21
1 7 8
2 11 10
3 r 3a
4 i a 0
* No rAFS for two subjects due to failure of recording equipment at site
(a) Blinded assessors assessed these as higher than stage 2
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42 patients completed the study and one withdrew due to nausea. This patient did under 
go a laparoscopy at week 12 however. Prior to unblinding all cases were reviewed to 
identify significant breaches of protocol and allow definition o f a per protocol set (PPS). 
Details of the numbers in each group are shown in table 5.4.
The valdecoxib study
A lloca tion  to  Per Protocol Set
T able 5.4 Subject Evaluation Groups
Valdecoxib Placebo
Randomised 43
Assigned to Study Treatment 43
Treated 22 21
Completed 22 20
Discontinued 0 1
Analyzed for Efficacy:
Full Analysis Set 22 21
Per Protocol Set 18 19
The six patients where excluded from the per protocol set for reasons shown in table 5.5
T able  5.5 Reasons for exclusion fro Per Protocol Set
Reason for Exclusion Valdecoxib Placebo
N N
Discontinuation due to nausea 0 1*
Stopped treatment one month prior to final 0 1
visit
Poor compliance with study medication 3 I *
Extreme r-AFS score at baseline 1 0
T ota l n u m b er o f subjects excluded 4 2
* This is the same subject
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Revised American Fertility Society Scores (rAFS)
The actual rAFS scores for each subject at baseline and 12 weeks are shown in table 5.6 
along with the change in score.
T able  5.6 rAFS scores and change from baseline
Baseline 
rAFS score
Valdecoxib 
12 weeks 
rAFS score
Change in 
rAFS score
Baseline 
rAFS score
Placebo 
12 weeks 
rAFS score
Change in 
rAFS score
6 .51 1.5 -5 4 4 0
28 27.5 -0.5 3.5 3 -0.5
9.5 3 -6.5 10 7.5 -2.5
6 3 -3 12.51 9 -3.5
61.51 41 -20.5 34.5 17 -17.5
2.5 2.5 0 6 6 0
9 9 0 4 5 1
N/A* 7 N/A 8 5 -3
N/A* 21.5 N/A 8.5 9.5 -1
12.5 23 10.5 1 2.5 1.5
10 8 -2 2.51 4 1.5
4* 6 2 4.5 5.5 1
6.5 7 0.5 0.5 3 2.5
4 8 4 8.5 12 3.5
3.5 1 -2.5 17 7 -10
8 11 3 10.5 6 -4.5
6 10 4 15 9.5 -5.5
3.5 0.5 -3 9 5 -4
5.5 3.5 -2 4 7 3
9 8.5 -0.5 12.5 7 -5.55
31 2.5 -0.5 30.5 12.5 -18
3 4 1
* Not available due to technical failure at site
1 Excluded from the per protocol set
Tw o subjects could not be included in any further analysis because they were missing 
b a s e l in e  r -A F S  d a ta  d u e  to  t e c h n ic a l  p ro b le m s  a t s i te .
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The change in rAFS stage at 12 weeks are shown in tables 5.7 -  5.10 for Full Analysis 
Set (FSA) and tables 5.11 -  5.13 for the Per Protocol Set (PPS) grouped according to 
rAFS stage at baseline.
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Table 5.7 Final rAFS stage of subjects with baseline r-AFS Stage=I -  FSA
Frequency W eek 12 r-AFS Stage
0 I II III IV Total
Valdecoxib 0 5 2 0 0 7
Placebo 0 6 2 0 0 8
Total 0 11 4 0 0 15
Table 5.8 Final rAFS stage of subjects with baseline r-AFS Stage=II -F S A
Frequency W eek 12 r-AFS Stage
0 I II III IV Total
Valdecoxib 0 4 6 1 0 11
Placebo 0 2 8 0 0 10
Total 0 6 14 1 0 21
Table 5.9 Final rAFS stage of subjects with baseline r-AFS Stage=III - F S A
Frequency W eek 12 r-AFS Stage
0 I II III IV Total
Valdecoxib 0 0 0 1 0 1
Placebo 0 0 2 1 0 3
Total 0 0 2 2 4
Table 5.10 Final rAFS stage of subjects with baseline r-AFS Stage=IV -  FSA
Frequency W eek 12 r-AFS Stage
0 I II III IV Total
Valdecoxib 0 0 0 0 1 1
Total 0 0 0 0 1 1
Note: Only subjects with both a baseline and week 12 r-AFS Stage are reported in these 
tables.
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T ab le  5.11 Final rAFS stage o f subjects w ith  baseline r-AFS Stage=I -  PPS
Frequency W eek 12 r-AFS Stage
0 I II III IV Total
Valdecoxib 0 4 1 0 0 5
Placebo 0 5 2 0 0 7
Total 0 9 3 0 0 12
T able  5.12 Final rAFS stage of subjects with baseline r-AFS Stage=II - P P S
Frequency W eek 12 r-AFS Stage
0 I II III IV Total
Valdecoxib 0 3 6 1 0 10
Double 0 2 7 0 0 9
Total 0 5 13 1 0 19
T able  5.13 Final rAFS stage of subjects with baseline r-AFS Stage=III -  PPS
Frequency W eek 12 r-AFS Stage
0 I II III IV Total
Valdecoxib 0 0 0 1 0 1
Placebo 0 0 2 1 0 3
Total 0 0 2 2 0 4
Note: Only subjects with both a baseline and week 12 r-AFS Stage are reported in these 
tables.
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A summary of the rAFS scores are shown in tables 5.14 and 5.15. Due to equipm ent 
failure at one site no recording was made at the first laparoscopy for two subjects. No 
rAFS scores are therefore available for baseline in these two subjects.
T able 5.14 Summary of Revised AFS Score -Full Analysis Set
Valdecoxib
(N=22)°
Placebo
(N=21)°
Baseline
N 20 21
M ean (s.d.) 10.1 (13.33) 9.8 (8 .78)
M edian (Min, Max) 6.3 ( 3 ,62 ) 8.5 ( 1,35)
W eek 12
N 22 21
M ean (s.d.) 9.5(10.10) 7.0 (3 .60)
M edian (Min, Max) 7.0 ( 1,41) 6.0 (3 , 17)
W eek 12 Change from Baseline1
N 20 21
M ean (s.d.) -1.1 (5 .87) -2.8 (6 .00)
M edian (Min, Max) -0.5 (-21, 11) -0.5 (-18, 4)
0 This is the total number of subjects in the treatment group in the indicated population.
1 Change from Baseline calculated only for subjects with a baseline and week 12 score.
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T ab le  5.15 Summary o f Revised AFS Score-Per Protocol Set
Valdecoxib
(N=18)°
Placebo
(N=19)°
Baseline
N 16 19
M ean (s.d.) 7.9 (6 .09) 10.1 (9 .06)
M edian (Min, Max) 6.3 (3 ,  28) 8.5 ( 1,35)
W eek 12
N 18 19
Mean (s.d.) 8.8 (7 .73) 7.1 (3 .69)
M edian (Min, Max) 7.5 ( 1,28) 6.0 (3 ,  17)
W eek 12 Change from Baseline1
N 16 19
M ean (s.d.) 0.2 (3 .89) -3.0 (6 .24)
M edian (Min, Max) -0.3 ( -7 , 11) -0.5 (-18, 4)
0 This is the total number of subjects in the treatment group in the indicated population.
1 Change from Baseline calculated only for subjects with a baseline and week 12 score.
On average, the placebo group showed a marginally greater reduction in r-AFS than the 
valdecoxib group, which dem onstrated little change (Table 5.16). There was no 
statistically significant difference between the valdecoxib and placebo groups in the mean 
change from baseline of the revised American Fertility Score (r-AFS).
T ab le  5.16 r-AFS Score, Change from Baseline to W eek 12 -  Per-Protocol Set
Valdecoxib 
20 mg bid 
N =  16
Double Blind 
Placebo 
N =  19
Treatment
Effect
95% Cl P-
value
r-AFS Score 
Baseline Mean (SE) 
Change from Baseline 
A djusted  mean* (SE)
7.9(1 .52) 
-0.4 (0.99)
10.1 (2.08) 
-2.6 (0.91) 2.2 (1.35) (-0.54, 4.96) 0.11
* ANCOVA containing terms for treatment and baseline r-AFS score
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T he appropria teness o f the  m odel w as checked  through residual analysis. T he 
robustness of the results was checked through a repeat analysis using the full analysis 
set (FA S)(p=0.1193) and a  non-param etric analysis using both full analysis and per- 
protocol sets. The im pact of the three subjects with baseline r-AFS greater than 20 on 
the per-protocol analysis was also  assessed. O verall conclusions w ere unchanged 
follow ing all of these analyses.
By using non-param etric tests, and hence m edians (Hodges-Lehm an estim ate of median 
treatm ent difference and exact W ilcoxon R ank Sum test) the influence o f outliers was 
reduced. The m edian change from  baseline is sim ilar within each treatm ent group (-0.3 
v -0.5 fo r valdecoxib and placebo respectively com pared to -0.4 v -2.6 for the m ean 
change). The m edian treatm ent d ifference and 95%  CI are sim ilar to  the param etric 
estim ates [2.0 (-1.5, 5), p=0.2742]. Overall conclusions rem ain unchanged
Overall there was no significant difference in change in rAFS score betw een the two 
groups when assessed using m eans, m edians, param etric tests, non param etric tests, per 
protocol groups or full analysis set.
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Four of the sets of paired lesions could not be analysed. In two, one of the images was of 
too poor quality to be able to define borders reliably and in a further two the pairs of 
lesions were not in fact the same lesion. The index lesion surface areas at baseline, twelve 
weeks and change in size are shown in appendix 3. A summary of the index lesion 
surface areas and change in surface areas are given in tables 5.17 -  5.20. Statistical 
analysis of the change in surface areas are shown in tables 5.21 and 5.22.
The valdecoxib study
Index lesion surface area.
107
The valdecoxib study
T ab le  5.17 Summary o f Index Lesion Size (m m 2)- F u ll Analysis Set
PARAM ETER N° n1
Baseline
Mean
(s.d)
Median 
(Min, Max)
N° n1
W eek 12
M ean Median 
(s.d) (Min, Max)
TOTAL AREA2
Valdecoxib 20 _ 10.7 4.4 20 - 11.1 3.0
(13.09) (0.3, 44.0) (16.90) (0.0, 65.3)
Placebo 19 - 7.1 2.4 19 14.3 3.3
(10.68) (0.5, 45.2) (25.94) (0.0, 106.2)
RED AREA
Valdecoxib 20 13 8.5 1.4 20 11 7.1 0.7
(13.18) (0.0, 41.6) (16.02) (0.0, 65.3)
Placebo 19 13 3.7 1.3 19 11 9.5 0.9
(5 .70) (0.0, 18.4) (25.02) (0.0, 106.2)
BLACK AREA
Valdecoxib 20 9 1.6 0.0 20 4 2.4 0.0
(4 .38) (0.0, 19.5) (9.11) (0.0, 40.7)
Placebo 19 6 1.0 0.0 19 7 1.1 0.0
(2 .49) (0.0, 9.7) (2 .46) (0.0, 9.6)
W HITE AREA
Valdecoxib 20 4 0.6 0.0 20 5 1.6 0.0
( 1.68) (0.0, 7.2) (3 .64) (0.0, 12.1)
Placebo 19 3 2.4 0.0 19 5 3.8 0.0
(9 .04) (0.0, 39.5) (10.06) (0.0, 40.2)
° Number of subjects with an index lesion assessment.
‘Num ber o f subjects whose index lesion assessment contains a non-zero red, black or 
white component respectively.
2 Total area of a lesion is the sum of the red, black or white areas.
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Table 5.18 Summary of Index Lesion Size change(mm2)- -Full Analysis Set
PARAMETER N
Week 12 Change from Baseline3
Mean (s.d) Median (Min, Max)
TOTAL AREA2
Valdecoxib 20 0.4 (8.87) -0.3 (-19.2, 21.4)
Placebo 19 7.2 (23.48) 0.1 (-15.1, 97.9)
RED AREA
Valdecoxib 20 -1.4(8.93) 0.0 (-29.0, 23.7)
Placebo 19 5.8 (24.24) -0.3 (-15.1, 97.9)
BLACK AREA
Valdecoxib 20 0.8 (4.92) 0.0 (-3.2, 21.2)
Placebo 19 0.0 (2.66) 0.0 (-9.7, 4.0)
WHITE AREA
Valdecoxib 20 1.0(3.55) 0.0 (-4.3, 11.6)
Placebo 19 1.4(4.69) 0.0 (-0.2, 20.4)
2 Total area of a lesion is the sum of the red, black or white areas.
Subjects must have both baseline and week 12 value to be included in the change from 
baseline summary.
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Table 5.19 Summary of Index Lesion Size (mm2)-Per Protocol Set
PARAMETER N° n1
Baseline
Mean
(s.d)
Median 
(Min, Max) 
N°
N° n1
Week 12 
Mean 
(s.d)
Median
(Min,
Max)
TOTAL AREA2
Valdecoxib 16 - 8.6 4.4 16 - 8.9 2.9
(9.99) (0.3, 30.7) (12.17) (0.0,40.7)
Placebo 17 - 7.7 2.8 17 - 15.6 3.3
(11.15) (0.5, 45.2) (27.21) (0.0,106.2
RED AREA
Valdecoxib 16 11 6.2 1.4 16 10 4.8 1.2
(10.17) (0.0, 30.3) (9.14) (0.0, 27.8)
Placebo 17 12 4.0 1.3 17 10 10.5 0.9
(5.94) (0.0, 18.4) (26.33) (0.0,106.2
BLACK AREA
Valdecoxib 16 5 1.7 0.0 16 3 3.0 0.0
(4.91) (0.0, 19.5) (10.17) (0.0,40.7)
Placebo 17 5 1.0 0.0 17 6 0.8 0.0
(2.62) (0.0, 9.7) (2.29) (0.0,9.6)
WHITE AREA
Valdecoxib 16 3 0.7 0.0 16 3 1.1 0.0
( 1.85) (0.0, 7.2) (3.07) (0.0, 12.1)
Placebo 17 3 2.7 0.0 17 5 4.2 0.0
(9.54) (0.0, 39.5) (10.58) (0.0,40.2)
° Number of subjects with an index lesion assessment.
‘Number of subjects whose index lesion assessment contains a non-zero red, black or 
white component respectively.
2 Total area of a lesion is the sum of the red, black or white areas.
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Table 5.20 Summary of Index Lesion Size change (mm2)- Per Protocol Set
PARAMETER N
Week 12 Change from Baseline3
Mean (s.d) Median (Min, Max)
TOTAL AREA2
Valdecoxib 16 0.3 (6.68) -0.3 (-10.1, 21.2)
Placebo 17 7.8 (24.82) 0.1 (-15.1, 97.9)
RED AREA
Valdecoxib 16 -1.4(2.83) -0.2 (-10.1, 2.5)
Placebo 17 6.5 (25.62) -0.3 (-15.1, 97.9)
BLACK AREA
Valdecoxib 16 1.3(5.40) 0.0 (-3.2, 21.2)
Placebo 17 -0.2 (2.62) 0.0 (-9.7, 3.9)
WHITE AREA
Valdecoxib 16 0.4 (2.83) 0.0 (-4.3, 10.2)
Placebo 17 1.6(4.94) 0.0 (-0.2, 20.4)
2 Total area of a lesion is the sum of the red, black or white areas.
3Subjects must have both baseline and week 12 value to be included in the change from 
baseline summary.
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Table 5.21 Summary of Statistical Analysis of Index Lesion Size(mm2)- Full Analysis 
Set
Hodges-Lehmann
N° Baseline Week 12 Week 12 Median 95% P
Median Median Median Change 
from Baseline
Treatment
Difference
CI Value1
TOTAL
AREA2
Valdecoxib 20 4.4 3.0 -0.3 -2.4 (-4.6,
0.7)
0.2038
Placebo 19 2.4 3.3 0.1
RED
AREA
Valdecoxib 20 1.4 0.7 0.0 0.0 (-2.9
0.4)
0.6884
Placebo 19 1.3 0.9 -0.3
BLACK
AREA
Valdecoxib 20 0.0 0.0 0.0 0.0 (-0.6,
0.0)
0.2025
Placebo 19 0.0 0.0 0.0
WHITE
AREA
Valdecoxib 20 0.0 0.0 0.0 0.0 (0.0,
0.0)
0.9305
Placebo 19 0.0 0.0 0.0
° Number of subjects used in the analysis. Only subjects with both baseline and week 12 
lesion size 
assessment are included in all analyses.
1 Exact P-value for Wilcoxon Rank Sum Test.
2 Total area of a lesion is the sum of the red, black and white areas.
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Table 5.22 Summary of Statistical Analysis of Index Lesion Size (mm2)- Per Protocol
Set
Hodges-Lehmann
N° Baseline Week 12 Week 12 Median 95% p
Median Median Median Change 
from baseline
Treatment
Difference
Cl Value1
TOTAL
AREA2
Valdecoxib 16 4.4 2.9 -0.3 -2.4 (-5.1,
1.1)
0.2604
Placebo 17 2.8 3.3 0.1
RED
AREA
Valdecoxib 16 1.4 1.2 -0.2 -0.1 (-3.0,
0.4)
0.6023
Placebo 17 1.3 0.9 -0.3
BLACK
AREA
Valdecoxib 16 0.0 0.0 0.0 0.0 (-0.1,
0.0)
0.5719
Placebo 17 0.0 0.0 0.0
WHITE
AREA
Valdecoxib 16 0.0 0.0 0.0 0.0 (0.0,
0.0)
0.5248
Placebo 17 0.0 0.0 0.0
0 Number of subjects used in the analysis. Only subjects with both baseline and week 12 
lesion size 
assessment are included in all analyses.
‘Exact P-value for Wilcoxon Rank Sum Test.
2 Total area of a lesion is the sum of the red, black and white areas.
There were no statistically different changes in surface area in any component (or total 
area) of the lesions in either the full analysis or per protocol set. Using the median 
treatment difference, as this is a small group and hence preferable to mean, there is a 
suggestion of a reduction in total surface area although this did not achieve statistical 
significance.
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VEGF concentrations
A summary of the VEGF concentrations are given in tables 5.23 and 5.24.
Table 5.23 Summary of VEGF Concentration (pg/ml)- Full Analysis Set
Valdecoxib
(N=22)°
Placebo
(N=21)°
Baseline
N
Mean (s.d.)
Median (Min, Max)
22
294.8 (522.77) 
110.0( 18,2295)
21
228.2 (304.61) 
102.1 ( 22,1188)
Week 12 
N
Mean (s.d.)
Median (Min, Max)
22
154.4(149.64) 
109.3 ( 15,672)
21
113.5(112.50) 
85.9 ( 6, 472)
Week 12 Change from Baseline1 
N
Mean (s.d.)
Median (Min, Max)
22
-140.4 (513.60) 
-0.5 (-1940, 585)
21
-114.7 (334.44) 
-18.4 (-1118, 409)
° This is the total number of subjects in the treatment group in the indicated population. 
1 Change from Baseline calculated only for subjects with a baseline and week 12 score.
Table 5.24 Summary of VEGF Concentration (pg/ml)- Per Protocol Set
Valdecoxib
(N=18)°
Placebo
(N=19)°
Baseline
N
Mean (s.d.)
Median (Min, Max)
18
324.0 (574.55) 
108.7 ( 18,2295)
19
242.3 (316.85) 
102.1 ( 22,1188)
Week 12 
N
Mean (s.d.)
Median (Min, Max)
18
138.4(156.01) 
91.1 ( 15, 672)
19
121.8(115.29) 
89.8 ( 6, 472)
Week 12 Change from Baseline1 
N
Mean (s.d.)
Median (Min, Max)
18
-185.5 (554.21) 
-1.2 (-1940, 585)
19
-120.5 (351.49) 
-18.4 (-1118, 409)
° This is the total number of subjects in the treatment group in the indicated population. 
1 Change from Baseline calculated only for subjects with a baseline and week 12 score.
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Statistical analysis of the change in VEGF concentrations are shown in tables 5.25 and 
5.26. These also show change in mean VEGF concentration when adjustment is made for 
the higher initial VEGF concentration in the valdecoxib group.
Table 5.25 Summary of Statistical Analysis of VEGF Concentration (pg/ml)- Full 
Analysis Set
Baseline Week 12 Change from 
Unadjusted Baseline
N° Mean (s.e.) Unadjusted Adjusted
Mean (s.e.) Mean1
_______________________________(s.e.)
Contrast of Treatment v 
Placebo2 
Diff 95% CI P 
(s.e.) Value
Valdec 22 
oxib
Placebo 21
294.8 
(111.45) 
228.2 
(66.47)
-140.4 
(109.50) 
-114.7 
(72.98)
-109.0 
(28.52) 
-147.6 
(29.20)
38.53 (-44.09, 0.3516
(40.88) 121.15)
° Number of subjects used in the analysis. Only subjects with both baseline and week 12 
values are included.
1 Least squares mean, adjusted for baseline.
2 Estimates based on comparison of least squares means.
Table 5.26 Summary of Statistical Analysis of VEGF Concentration (pg/ml)- Per 
Protocol Set
Baseline Week 12 Change from Contrast of Treatment v
N°
Unadjusted 
Mean (s.e.)
Baseline 
Unadjusted Adjusted 
Mean (s.e.) Mean1 (s.e)
Diff
(s.e.)
Placebo2 
95% CI P
Value
Valdec 18 324.0 -185.5 -145.3 13.22 ( (-78.86, 0.7723
oxib (135.42) (130.63) (32.40) 45.31) 105.29)
Placebo 19 242.3 
(72.69)
-120.5 -158.5 
(80.64) (31.53)
0 Number of subjects used in the analysis. Only subjects with both baseline and week 12 
values are included.
1 Least squares mean, adjusted for baseline.
2 Estimates based on comparison of least squares means.
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There was no statistically significant difference in change in VEGF concentration 
between the two groups. The initial mean VEGF concentration was lower in the placebo 
group. Both groups showed a reduction in VEGF concentration from week 0 to week 12.
The valdecoxib study
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Visual Analogue Scales for pain 
W eek 0, 6  and  12 assessm ents
The VAS scores for pain as assessed at weeks 0, 6 and 12 for the preceding 4 weeks are 
shown in tables 5.27 and 5.28 and figures 5.1 -  5.4.
Statistical analysis of these figures are shown in tables 5.29 and 5.30.
In all categories the valdecoxib group had greater pain reduction than the placebo group. 
None of the differences were statistically significant however.
The appropriateness of the models was checked through residual analysis. The robustness 
of the results was checked through an exact Wilcoxon Rank Sum test using both full 
analysis and per protocol sets. Conclusions were unchanged following these analyses.
The valdecoxib stud}'
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The VAS scores for the weekly pain assessments are given in tables 5.31.1 -  5.31.3 and 
5.32.1 -.5.32.3 and figures 5.5 -  5.7.
There was wide variation in the confidence intervals for all parameters with marked 
overlap between the groups. There were no particular trends and no statistical analysis 
was carried out.
The valdecoxib study
Weekly assessments
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A summary of the EHP 30 scores and statistical analysis are shown in tables 5.33 -  5.36. 
The only statistical difference between the two groups was in the sexual relationship 
category with improvement seen in the placebo group and the valdecoxib group 
remaining relatively unchanged. Virtually all other categories in both groups showed 
improvement compared to baseline but this was not statistically significant between 
groups.
The valdecoxib study
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When considering any of the results from this study it is important to remember this was 
a small study with results showing a relatively large degree of variability. As such it’s 
ability to detect significant change is somewhat limited unless the difference between the 
two groups is very large.
The revised AFS scoring system was used as an end point as it is a well recognised 
method of documenting endometriosis and is the standard tool used in studies looking at 
disease progression / regression. However, prior to commencement it was recognised that 
this was a rather limited tool for this study. The system was developed as a means of 
correlating disease with fertility and as such is very biased to disease of the ovaries and 
fallopian tubes. In fact the highest scored that can be assigned to disease of the 
peritoneum on its own is six. Thus if a patient has extensive deep peritoneal 
endometriosis covering for example an area of 10.6cm2, as was the area found in one 
lesion in the digital analysis, she would be allocated the same score as another patient 
with a lesion of 3.8cm2. Clearly these are very different cases and the chance of these 
lesions regressing enough over three months for them to be allocated a difference score 
are very low in the first case but quite possible in the second. Equally, the degree of 
change in score possible is limited by the baseline value. A patient with a baseline score 
of three for example, may progress either upwards or downwards with regard to score 
where as a patient allocated six at baseline can only regress numerically or stay the same. 
It is not possible for the disease to progress using the rAFS score if we are only interested 
in peritoneal disease. Equally a patient with an initial rAFS score of one can only
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possibly improve by a maximum of one rAFS point where as, from the point of view of 
peritoneal disease, she may progress by another five points. Those patients who did have 
rAFS values greater that six recorded must have had contributions to the score made by 
ovarian disease, disease of the cul de sac and / or adhesive disease. None of these were 
required to test the hypothesis that valdecoxib causes regression of active peritoneal 
endometriosis over a three month period.
In addition to the above limitations of the rAFS scoring system there is also the question 
of reproducibility. To a large extent, the allocation of points is subjective and not only 
relies of a ‘guestimate’ of surface area by the operator but also a subjective assessment of 
depth of disease. Whilst some have described the inter and intra observer variability as 
‘good to fair’ [173] others have found it to be poor [174]. To help reduce such variability 
the rAFS score for each subject was assessed independently by two assessors viewing the 
video recordings of the abdominopelvic cavity. The mean result of these were then used 
in calculation. As a consequence of this however, the chances of the rAFS score 
remaining unchanged between baseline and week 12 are reduced.
The inter observer variability of this scoring system is demonstrated by the fact that in 5 
cases the baseline mean rAFS score allocated was greater than 15 meaning the subjects 
had worse than stage two disease. As the entry criteria for randomisation at baseline 
laparoscopy was rAFS stage 1 or 2 then the investigators at the sites must have given an 
rAFS score of less than 15 at the time of laparoscopy to be able to randomise the patient.
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In view of all these limitations an additional method of quantification was developed to 
assess change in endometriotic lesions as described in the methodology study.
Accepting all the limitations of the rAFS scoring system, there was no difference in 
disease regression between the valdecoxib group and the placebo group, both of which 
showed a slight reduction in rAFS score. Comparing the means of the two groups gives 
the impression of a non significant reduction in the placebo group compared to the 
valdecoxib group (p=0.1109) however these are excessively influenced by the extreme 
outliers in each set (28 & 61.5 in the valdecoxib group and 30.5 and 34.5 in the placebo 
group). Thus, the median values are more representative in this comparison and they 
show the slight reduction is similar for each group with no suggestion of difference 
between the groups.
When using the change in index lesion as a marker of disease regression, in keeping with 
the rAFS score results, there is no evidence of significant disease regression in the 
valdecoxib group. There was large variation in the size of lesions at baseline (0.3- 
45.2mm2) and at twelve weeks (0.0-106.2 mm2) making statistical significance in a 
relatively small group unlikely. Additionally 28 of the 39 pairs analysed had only one 
component to the total lesion size making it impossible to analyse the change in different 
components of the lesions in any meaningful way. There was however very good 
correlation between change in the red component of the lesions and total change in 
surface area with a correlation coefficient of 0.96. As explained previously, by virtue of 
the fact that the red areas are most active and therefore most likely to respond to
Tlie valdecoxib study
147
treatment, the use of change in total surface area is a reasonable surrogate. There was 
very little correlation between change in black component (correlation coefficient 0.05) 
or white component (correlation coefficient 0.02) with change in total surface area.
The fact that so many of the lesions had only one component would imply that such 
lesions where relatively ‘simple’ and as such should have been easy to demarcate. The 
assessments were undertaken by assessor 1 from the methodology study who had 
demonstrated a high level of reproducibility. Only 11 of the 39 pairs of lesions had a total 
surface area of more than 15mm2 in either or both images. By referring to the data from 
the methodology study for this assessor, lesions below this size appeared to have better 
reproducibility than larger lesions. This, combined with the relative simplicity of most 
lesions would suggest the apparent change in surface areas observed are probably a 
relatively accurate reflection of the true change in the lesion.
Overall, using two methods of assessing, there is no evidence that valdecoxib is effective 
in causing disease regression in peritoneal endometriosis. The question is, is this because 
there were problems with the study or does the inhibition of COX 2 by valdecoxib fail to 
inhibit endometriosis despite the scientific rationale outlined earlier? The answer may be 
both. The study was small with quite marked variability within it and from this point of 
view demonstrating small differences is unlikely. However, for ethical reasons and to 
reduce variability, the inclusion criteria for randomisation was rAFS stage 1 or 2 disease 
only. On the whole, such patients will have smaller plaques of endometriosis on their 
peritoneal surfaces than those with more severe advanced disease. One of the main
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rationales for the efficacy of valdecoxib in causing disease regression was by its 
inhibition of endometriotic angiogenic activity. By inhibiting COX 2 the angiogenic 
agents PGtft and VEGF should also be reduced. The requirement of angiogenesis by a 
lesion will only become necessary when the lesion reaches a certain size. In tumour 
studies this is around 1mm3 [69-71]. In addition the metabolically most active part of 
endometriotic lesions are the red areas [169] with significantly less activity in the black 
and white areas. In our study 13 of the 39 index lesions had no red areas at all at baseline 
and a further 5 had a total red surface area of less than 1mm2. Assuming a depth of 1mm 
or less this would mean 18 of 39 baseline lesions had an ‘active’ volume of less than 
1mm3 and may well not be particularly angiogenically active. Further support for lack of 
angiogenic activity in this early stage is provided by the VEGF concentrations. The 
median levels observed of around 100 to 110 pg/ml are in fact lower than those levels 
found in the no endometriosis and peritoneal endometriosis score less than or equal to 
five groups observed in the Mahnke study, who found median VEGF concentrations of 
207 pg/ml and 197pg/ml respectively [175]. This study also found no difference in 
concentrations of peritoneal fluid VEGF between the no endometriosis and peritoneal 
endometriosis with an rAFS score of five or less. They were able to demonstrate a 
significant increase in peritoneal fluid concentration in patients with peritoneal rAFS 
score of six or more when compared to no endometriosis or endometriosis with an rAFS 
score of five or less, suggesting this is when angiogenesis becomes important. In our 
study 15 of the subjects had baseline rAFS scores of five or less and would thus be likely 
to be producing relatively little VEGF to begin with.
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The other postulated mechanism of action for valdecoxib was the reduction in active 
COX2 causing decreased aromatase activity and thereby reduced local oestrogen 
production. Whilst local production of oestrogen has been shown to perpetuate residual 
endometriosis in post menopausal and oophorectomised women [100, 101], these have 
occurred in women with previously severe disease and presumably large deposits. In our 
population, because of the early stage, most deposits are small and cumulatively probably 
producing relatively little oestrogens. Additionally, all subjects had normal ovarian 
function and as such the quantity of ovarian produced oestrogen will far outweigh any 
produced (or not produced) by the individual small endometriotic deposits. Thus by 
selecting the population as we did, it is possible we have selected a group that is least 
likely to respond to such treatment.
The duration of the study was also relatively short. In previous comparable studies 
treatment lasted between three and six months with laparoscopies between four and six 
months [106, 107, 117, 123]. The median treatment difference in total surface area in the 
valdecoxib group compared to placebo was -2.4 mm2 in favour of valdecoxib. This 
difference was statistically non significant (p=0.2038) however it may be that, had 
treatment carried on longer than three months, this difference may have been greater and 
a statistically significant difference may have become apparent.
Despite these problems of limited disease severity, small numbers and short duration of 
the study there are other characteristics of the study that methodologically are superior to 
the previously mentioned studies. Most studies using laparoscopic assessment of disease
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as an end point have laparoscoped patients at the end of treatment. However, as all 
previous treatments (with the exception of cyclical dydrogesterone [115]) have 
suppressed ovarian function it is probable immediate laparoscopy at the end of treatment 
will under estimate disease as deposits may be quiescent until normal ovarian function 
resumes [162]. Because valdecoxib does not interfere with ovarian function we were able 
to undertake laparoscopy immediately on cessation of treatment with out the possibility 
of missing quiescent disease. Equally because of normal ovarian function, the menstrual 
cycle was unaffected meaning incidental unblinding of both patient and investigator did 
not occur due to amenorrhoea.
The effect of valdecoxib on pain was as expected. As a known analgesic one would 
expect pain to be reduced in the valdecoxib group compared to the placebo group. This 
was true for all pain variables and the combined pain score. In no case did this achieve 
statistical significance, however the trend was consistent throughout and had the study 
numbers been greater one would expect statistical significance to be achieved. It is 
interesting to note that, as has been shown in other studies [116, 176, 177], there is a 
marked placebo effect with a 25.5% (33.7/131.9) reduction in pain score between 
baseline and week 12 in the placebo group. This confirms the importance of any study 
into endometriosis having a placebo control group, especially when a subjective endpoint 
such as pain is used.
The change in peritoneal fluid VEGF concentration showed no significant difference 
between the two groups.
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The relatively low peritoneal fluid VEGF concentrations have been discussed and are in 
keeping with those of Mahnke [175]. It is interesting to note that these are around 100- 
fold lower than those in the McLaren [86] study. The suggestion of Mahnke for this 
difference is that different assays were used. This study and that by Manhke both used 
commercially produced VEGF assays where as that of McLaren was an in-house assay. It 
is difficult to think of any other explanation for this discrepancy.
Both mean and median peritoneal fluid VEGF concentrations were reduced in the week 
12 samples compared to baseline in each group. The probable explanation for this relates 
to the stage of menstrual cycle when the sample was obtained. VEGF concentrations are 
known to be reduced in the secretory phase of the menstrual cycle of patients with 
endometriosis [86]. All subjects in this study were in the proliferative stage of the cycle at 
baseline, however because not all women have regular 28 day cycles, by the second 
laparoscopy (at week 12) 16 were in the secretory phase (eight in each group).
With the exception of the effect on sexual relationships, the lack of effect on quality of 
life as assessed by the EHP-30 was not unexpected. Just about all categories assessed 
showed improvement from baseline but with no difference between the groups. Apart 
from pain, the other categories are very much to do with mental ‘states of mind’ such as 
self image and powerlessness and it would be unlikely that a treatment would have a 
significant effect on such areas in such a short period of time. The significant difference 
in effect on sexual relationships is difficult to explain. Three of the five questions in this
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section relate to pain, (have you experienced, felt worried about or avoided intercourse 
because of pain) and there was a consistent improvement in pain in the valdecoxib group 
over placebo for all pain assessment made by VAS. The number of subjects used for this 
analysis was significantly less than that of the whole group (28/43) as the question was 
‘not relevant’ for the remainder of subjects. As there is no obvious explanation for such 
discrepancy one can only assume this may have arisen by chance.
Overall this study does not support the hypothesis that valdecoxib is effective in causing 
regression of peritoneal endometriosis over a period of three months in patients with 
minimal or mild disease. It is theoretically possible that it may be effective in more 
advanced disease, however, this would require a further study with an additional method 
of disease quantification to quantify volume of disease rather than just rAFS score and / 
or surface area.
5.5 Conclusions
This study has not demonstrated any significant difference in disease progression / 
regression between those patients treated with valdecoxib and those treated with placebo 
as assessed by both rAFS score and index lesion surface area analysis.
Secondary end point analysis of pain and quality of life equally did not demonstrate any 
significant difference between the two groups with the exception of a significant 
improvement in sexual relationships in the placebo group compared to the valdecoxib
The valdecoxib study
153
group. Whilst pain scores were not statistically different there was a definite trend to 
reduced pain scores in the valdecoxib group compared to placebo.
There was no significant difference in concentration of VEGF between the two groups.
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C h a p te r  6 
S u m m a ry  a n d  C onc lus ions
Summary and conclusions
It is very clear that the quality of published research into endometriosis is generally poor. 
For a condition described nearly 150 years ago it is amazing that the first RCT into 
treatment of the condition was not published until 1987 and even more disappointing that 
only five studies in total actually contain a placebo arm and document change in disease. 
Based on this lack of data however, millions of women worldwide are being treated with 
a wide range of different regimens, with very little support for their efficacy. In some 
cases, by either side effects or possibly the masking of progressive disease, they are being 
exposed to potential harm. This lack of or miss information is compounded by the fact 
that there are numerous studies that compare one treatment with another. This could only 
be a valid technique if the treatment used as the comparator is proven to be efficacious 
when compared to placebo. Chapter two has clearly shown that on the whole this data is 
lacking. From this extensive search one can only conclude that MPA and luteal phase 
dydrogesterone are probably ineffective, the benefits of either danazol or triptorelin are 
inconclusive and that, from one small study, gestrinone appears to be more effective than 
placebo.
Numerous new strategies for endometriosis are being proposed including GnRH 
antagonists, progesterone receptor modulators, other anti angiogenic agents and 
aromatase inhibitors. Whilst all these are welcome, and will hopefully represent a 
significant advance in the management of this condition, it is essential, before their 
introduction into standard gynaecological practise, that they show efficacy in causing 
disease regression as well as symptomatic relief. This efficacy must be demonstrated by
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comparison to placebo and not other, older, unproven compounds if claims of efficacy 
are to be valid.
The lack of understanding of the natural history of endometriosis remains a problem in 
day to day gynaecology. This clearly makes clinical decisions and patient counselling 
difficult as one is unable to predict outcome if untreated. The conclusions of chapter three 
must be viewed with caution as, as explained in the text, there are considerable 
difficulties in combining various studies and thus statistically the results are not as robust 
as one would like. That said, the information represents a ‘best guess’ based on available 
evidence, as to what happens to endometriosis untreated. From this it would appear the 
chances of progression and regression are approximately equal. The difficulty in clinical 
practice is it is not possible to predict the behaviour of the disease in each individual case. 
In view of this it is concluded, along with other authors, that in the majority of cases one 
should to treat patients in whom the diagnosis of endometriosis is made. Clearly 
however, it is important to consider the individual circumstances and, as explained in 
chapter 3, there will be circumstances such as incidental endometriosis discovered during 
laparoscopic sterilisation, that may be left untreated. Future studies into the natural 
history of the disease as a primary end point are very unlikely to be performed for two 
main ethical reasons. Whilst the disease if left untreated is unlikely to lead to death, as in 
for example abnormal cervical cytology [178], in some cases it will progress to more 
advanced disease. This advanced disease may involve both gynaecological and non- 
gynaecological abdominopelvic organs with possible severe consequences. Progressive 
disease of the gynaecological organs may render the patient permanently infertile whilst
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that involving the bowel or urinary tract may cause permanent damage to these structures. 
Surgical procedures to deal with these complications would then become much more 
extensive than would have been required had the disease not been left untreated with 
associated increased morbidity and in rare cases mortality. The second ethical problem of 
following untreated endometriosis is the method of quantifying disease. At present the 
accepted method of quantification is the rAFS scoring system. This requires a 
laparoscopy and clearly should one wish to follow the natural history of the disease 
untreated, at least two if not more laparoscopies would be required. There would not be 
any significant benefit of the second laparoscopy to an individual patient taking part in a 
study, but there would undoubtedly be some risk with around 2 in 1000 suffering a 
significant complication and 3-8 in 100,000 dying as a consequence of the procedure 
[179, 180]. Whilst one may argue that such studies will provide information that, by 
informing clinicians and patients of chance and risk factors for progression, will allow 
less women to be treated and thereby cause less complications overall, ethically, one 
must be acting in the best interest of the individual patient rather than the patient body as 
a whole and thus such follow up studies would be unethical.
With time, increasing numbers of placebo controlled trials will be published and the 
available data from placebo arms of these studies will increase. It is accepted that this 
population may not be truly representative of the population as a whole, being highly 
motivated subjects who have met numerous inclusion and exclusion criteria, but 
pragmatically and for the ethical reasons just outlined it is probable this will be our main 
source of data. With the increased numbers and hence statistical power the true natural
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history of the disease will hopefully become apparent, albeit by a rather convoluted 
method of study. This increased data will hopefully make it possible to determine 
identifiable factors that would alter the chances of disease progression. With such 
information the clinician and patient will be far better informed as to disease behaviour in 
an individual case and there by be able to avoid unnecessary treatment in those 
individuals in whom the disease is likely to regress spontaneously.
To continue to evaluate new treatments of endometriosis it is clear a more sensitive tool 
than the rAFS score alone is required. The lack of discriminatory power of the scoring 
system for peritoneal disease, as outlined in chapter four, may well limit the abilities of 
studies to detect changes in disease and thereby cause important benefits to be missed. 
For ethical and commercial reasons it is not possible to run studies into new treatments 
for prolonged periods of time and, as such, a test that can detect more subtle changes in 
lesion size would be of great value. The detection of subtle, possibly clinically 
insignificant change within a short time frame will allow researchers to decide whether a 
particular line of enquiry is worth pursuing and allow ethical approval for longer more 
pragmatic studies to be sought. The lesion analysis method described in chapter four 
provides a relatively simple and reproducible method of quantifying change in individual 
lesions. The inter observer error was rather poor but the intra observer error was 
considerably better. By defining an individuals intra observation error, one is 
immediately aware of the level of treatment related difference between the groups which 
one is able to detect . It would be advised that future studies quantifying change in 
disease use similar semi automated techniques and hopefully over time a standardised
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tool, similar to the rAFS scoring system, will be developed to allow comparisons between 
studies to be made. These tools will need to be carefully evaluated for variability and 
reproducibility. If one is to consider studying more advanced disease, the simple process 
of quantifying disease by surface area however, will probably prove inadequate. 
Advanced disease is associated with deeper deposits of endometriosis as it ‘invades’ into 
the adjacent tissue and to simply quantify the disease visible on the surface is really 
measuring the ‘tip of the iceberg’. Methods of quantifying disease volume are thus 
clearly needed to allow significant progress in this area. Despite efforts with MRI [37-39] 
to date a reliable technique is yet to be developed and clearly this is an area where further 
research is needed.
Non invasive techniques of disease quantification such as MRI, if proven reliable and 
reproducible, would clearly be invaluable in studying disease progression as well as 
assessing the efficacy or otherwise of any new treatment. Provided the techniques do not 
involve risk of significant harm to subjects there would be no ethical problems with 
monitoring disease, thereby giving a much clearer picture of the natural history of the 
condition. Equally it would allow the clinician much more scope to adopt an expectant 
approach to the disease in many patients, confident in the knowledge that it is easy to 
identify those patients in whom the disease is progressing and thus allow treatment at an 
earlier stage.
To be useful in large scale studies such techniques would need to be semi if not fully 
automated. The quantification of the lesions in the valdecoxib study required around 58
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man hours and this was for analysis of only 78 lesions. In a large study such analysis 
would not be possible. The identification of the individual components of the lesions 
showed significant variability between the observers using the digital imaging technique 
described earlier, as the designation of the areas of the lesion into red, white or black was 
very subjective. For an automated system to perform this accurately would therefore be 
virtually impossible. If however, as in the case of MRI, the image is in grey scale it may 
be possible for a system to measure total lesion volume with some degree of 
reproducibility.
Despite a rational and multifaceted postulated hypothesis as to why COX-2 inhibition 
should cause disease regression, there was no evidence for this in the randomised 
controlled trial of valdecoxib in chapter five. The fact that there was a lack of change is 
reinforced by the fact that two independent methods were employed to quantify disease. 
The overall design of the study was of high quality being truly randomised, blinded and 
placebo controlled. Although numbers are small, the fact that the results with regard to 
change in disease did not even suggest a trend would lead one to conclude, with a 
reasonable degree of confidence, that the treatment was ineffective. What cannot be 
concluded is that this is true of all cases of endometriosis. As explained, the lack of 
efficacy in this group may have been because of inappropriate patient selection. The 
postulated mechanisms of action rely on various activity within the endometriosis lesions 
that may not in fact be very active in this early stage of disease. Thus one must conclude, 
that the efficacy of valdecoxib in treatment of moderate and severe endometriosis is 
unknown. The known analgesic effect of COX-2 inhibitors was supported by the
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evidence, although because the study was not powered for pain, it did not achieve 
statistical significance.
Due to the lack of any previous studies into COX 2 inhibitors and endometriosis, and the 
lack of any meaningful idea as to what constituted a clinically significant effect of 
treatment when using disease regression as an outcome, it was not possible to do a logical 
power calculation to guide the size of the study. In effect this was a proof of concept 
study designed to test not only that valdecoxib did cause disease regression but also to 
provide information to guide further studies as to numbers required to show a statistically 
significant effect. Because there was no consistent trend in change in disease using either 
rAFS scoring system or digital imaging, this study is not able to provide this information. 
The fact that this was a well designed, randomised, placebo controlled trial and that there 
was not even any suggestion of benefit using two methods of quantification of diseases 
would probably suggest there is little point in pursuing further studies in this area on this 
group of patients. Obviously this cannot be extrapolated to all patients with endometriosis 
where further study may well be justified, but in the selected group of patients in this 
study, there appeared to be no benefit with regard to disease regression at all.
Since the conclusion of this experiment there has been significant concern with regard to 
the safety of COX 2 inhibitors. In the APC study investigating the use of celecoxib in 
preventing the development of adenomatous colonic polyps, there appeared to be an 
increase in the rate of myocardial infarction and there have been similar findings with the 
COX 2 inhibitor rofecoxib causing its withdrawal from the market. At present it is
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unclear whether this is a class effect or a drug specific effect and as a consequence there 
is significant concern surrounding the safety of these drugs[181-184]. Until further 
investigations are complete it would seem inappropriate to undertake further studies of 
these compounds in the treatment of endometriosis.
In conclusion, current knowledge of the aetiology, natural history and effectiveness of 
medical therapy for the treatment of endometriosis remains very limited. It is the 
responsibility of all professionals working in this area to strive to increase this 
understanding and ensure that any new approaches to therapy are appropriately tested 
prior to their adoption into routine clinical practice, for the benefit of both patients and 
health care delivery systems worldwide.
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Appendix 1
Dysm enorrhoea (period pain)
Have you menstruated (had a period) during the last 7 days?
Please tick appropriate box Y □ N □
If yes,
please place a vertical line across the horizontal line below (for example, — j—) at the point which 
describes how much period pain you have experienced.
No      Worst
Pain Imaginable pain
Non-»m@nstrual pelv ic pain (pe lv ic  pain no t related to  m enstruation)
Have you experienced any pelvic or lower abdominal pain that was not related to your period 
(menstruation) over the last 7 days?
Please tick appropriate box YD N □
If yes,
please place a vertical line across the horizontal line below (for example, — at the point 
which describes how much pelvic pain you have experienced in the last 7 days.
No ___________________ _________________________________  Worst
Pain Imaginable pain
Dyspareunia (pa infu l sexual in tercourse)
Have you experienced sexual intercourse during the last 7 days?
Please tick appropriate box YD N D 
If yes,
please place a vertical line across the horizontal line below (for example, —|—) at the point 
which describes how much pain you have experienced during sexual intercourse in the last 7 
days.
No     Worst
Pain Imaginable pain
A ppendix 2
Part 1: Core Questionnaire
DURING THE LAST 4 WEEKS, HOW OFTEN BECAUSE OF YOUR 
ENDOMETRIOSIS HAVE Y O U .......
Never Rarely Sometimes Often Always
Been unable to go to social events because 
of the pain? □ □ □
□ □
Been unable to do jobs around the home 
because of the pain? D □ □ □ □
Found it difficult to stand because of the 
pain? □ □ □ □ □
Found it difficult to sit because of the pain? □ □  ' □ □ □
Found it difficult to walk because of the 
pain? □ □ □ □ □
Found it difficult to exercise or do the 
leisure activities you would like to do 
because of the pain?
□ □ □ □ □
Lost your appetite and/or been unable to 
eat because of the pain? □ □ □ □ □
D U R IN G  TH E L A S T  4 W E E K S , H O W  O F T E N  B E C A U SE  
O F Y O U R  E N D O M E T R IO SIS  H A V E  Y O U ......
Never Rarely Sometimes Often Always
Been unable to sleep properly because of 
the pain? □ □ □ □ □
Had to go to bed/lie down because of the 
pain? □ □ □ □ □
Been unable to do the things you want 
because of the pain? □ □ □ □
□
Felt unable to cope with the pain? □ □ □ □ □
Generally felt unwell? □ □ □ □ □
Felt frustrated because your symptoms are 
not getting better? □ □ □ □
□
Felt frustrated because you are not able to 
control your symptoms? □ □
□ □ □
DURING THE LAST 4 WEEKS, HOW OFTEN BECAUSE OF YOUR 
ENDOMETRIOSIS HAVE Y O U .......
Never Rarely Sometimes Often Always
Felt unable to forget your symptoms? □ □ □ □ □
Felt as though your symptoms are ruling 
your life? □ □ □ □ □
Felt your symptoms are taking away your 
life? □ □ □ □ □
Felt depressed? □ □ □ □ □
Felt weepy/tearful? □ □  ' □ □ □
Felt miserable? □ □ □ □ □
Had mood swings? □ □ □ □ □
Felt bad tempered or short tempered? □ □ □ □ □
HOW OFTEN DURING THE LAST 4 WEEKS, HOW OFTEN BECAUSE OF 
YOUR ENDOMETRIOSIS HAVE Y O U .......
Never Rarely Sometimes Often Always
Felt violent or aggressive? □ □ □ □ □
Felt unable to tell others how you feel? □ □ □ □ □
Felt others do not understand what you are 
going through? □ □ □ □ □
Felt as though others think you are 
moaning? □ □ □ □ □  .
Felt alone? □ □ □ □ □
Felt frustrated as you cannot always wear 
the clothes you would choose? □ □ □ □ □
Felt your appearance has been affected? □ □ □ □ □
Lacked confidence? □  □  □  □  □
Part 2: These questions concern the effect endometriosis has had on your 
sexual relationships during the last 4 weeks
D U R IN G  T H E  L A S T  4 W E E K S, H O W  O FT E N  BE C A U SE  
O F  Y O U R  E N D O M E T R IO SIS  H A V E  Y O U ......
Never Rarely Sometimes Often Always
Experienced pain during or after 
intercourse?
if not relevant please tick here □
□ □ □ □ □
Felt worried about having intercourse 
because of the pain?
If not relevant please tick here D ^
□ □ □ □ □
Avoided intercourse because of the pain? 
If not relevant please tick here □
□ □ □ □ □
Felt guilty about not wanting to have 
intercourse?
If not relevant please tick here □
□ □ □ □ □
Felt frustrated because you cannot enjoy 
intercourse?
If not relevant please tick here □
□ □ □ □ □
Appendix 3
Index Lesion Surface Area at Baseline
Subject Randomisation Red Area 
(mm2)
Black Area 
(mm2)
W hite Area 
(mm2)
Total Area 
(mm2)
001001 Valdecoxib 29.02 1.75 0.00 30.77
001031 Valdecoxib 19.26 0.00 0.00 19.26
001005 Valdecoxib 0.00 0.00 7.21 7.21
001015 Valdecoxib 30.27 0.43 0.00 30.70
001044 Valdecoxib 4.81 0.00 0.00 4.81
001006 Valdecoxib N/A N/A N/A N/A
001018 Valdecoxib 5.79 0.00 0.00 5.79
001036 Valdecoxib 3.84 0.00 0.00 3.84
001045 Valdecoxib 0.00 0.59 0.00 0.59
001033 Valdecoxib 0.53 0.00 0.00 0.53
001012 Valdecoxib 3.19 0.00 0.00 3.19
001021 Valdecoxib 28.08 0.00 0.00 28.08
001006 Valdecoxib N/A N/A N/A N/A
001043 Valdecoxib 0.33 0.00 0.00 0.33
001017 Valdecoxib 2.44 0.00 0.00 2.44
001051 Valdecoxib 0.00 0.07 1.80 1.87
001010 Valdecoxib 0.00 0.37 1.71 2.08
001002 Valdecoxib 0.00 3.94 0.00 3.94
001030 Valdecoxib 0.50 0.00 0.00 0.50
001025 Valdecoxib 0.00 3.19 1.87 5.06
001028 Valdecoxib 0.00 19.53 0.00 19.53
001023 Valdecoxib 41.62 2.33 0.00 43.95
001011 Placebo 15.14 0.00 0.00 15.14
001048 Placebo 18.40 0.00 0.00 18.4
001013 Placebo N/A N/A N/A N/A
001046 Placebo 12.96 0.00 0.00 12.96
001009 Placebo 1.37 0.00 0.00 1.37
001050 Placebo 1.26 0.00 0.00 1.26
001003 Placebo 0.00 0.71 1.64 2.35
001007 Placebo 1.92 0.00 0.00 1.92
001034 Placebo 0.45 0.00 0.00 0.45
001022 Placebo 1.61 0.00 0.00 1.61
001037 Placebo N/A N/A N/A N/A
001004 Placebo 0.00 1.03 0.00 1.03
001024 Placebo 1.09 0.00 0.00 1.09
001035 Placebo 0.45 0.00 0.00 0.45
001027 Placebo 2.79 0.00 0.00 2.79
001008 Placebo 0.00 1.81 0.00 1.81
001026 Placebo 0.00 0.67 4.19 4.86
001019 Placebo 0.00 5.70 39.47 45.17
001020 Placebo 3.82 0.00 0.00 3.82
001014 Placebo 0.00 9.69 0.00 9.69
001029 Placebo 8.33 0.00 0.00 8.33
Index Lesion Surface Area at 12 weeks
Subject Randomisation Red Area 
(mm2)
Black Area 
(mm2)
W hite Area 
(mm2)
Total Area 
(mm2)
001001 Valdecoxib 0.00 0.00 11.62 11.62
001031 Valdecoxib 9.13 0.00 0.00 9.13
001005 Valdecoxib 0.00 0.00 2.94 2.94
001015 Valdecoxib 27.17 0.00 0.00 27.17
001044 Valdecoxib 1.44 0.00 0.00 1.44
001006 Valdecoxib N/A N/A N/A N/A
001018 Valdecoxib 2.47 0.00 0.00 2.47
001036 Valdecoxib 1.05 0.00 0.00 1.05
001045 Valdecoxib 0.00 0.00 0.00 0.00
001033 Valdecoxib 0.00 0.00 0.00 0.00
001012 Valdecoxib 2.09 0.73 0.00 2.82
001021 Valdecoxib 27.78 0.00 0.00 27.78
001006 Valdecoxib N/A N/A N/A N/A
001043 Valdecoxib 0.29 0.00 0.00 0.29
001017 Valdecoxib 2.48 0.00 0.00 2.48
001051 Valdecoxib 0.00 0.00 2.63 2.63
001010 Valdecoxib 0.00 0.64 2.50 3.14
001002 Valdecoxib 0.00 5.90 0.00 5.90
001030 Valdecoxib 3.02 0.00 0.00 3.02
001025 Valdecoxib 0.00 0.00 12.05 12.05
001028 Valdecoxib 0.00 40.70 0.00 40.70
001023 Valdecoxib 65.31 0.00 0.00 65.31
001011 Placebo 0.00 0.00 0.00 0.00
001048 Placebo 13.46 0.00 0.00 13.46
001013 Placebo N/A N/A N/A N/A
001046 Placebo 10.21 0.73 0.00 10.94
001009 Placebo 0.95 0.00 0.00 0.95
001050 Placebo 0.88 0.00 0.00 0.88
001003 Placebo 0.00 0.56 1.41 1.97
001007 Placebo 1.59 0.00 0.00 1.59
001034 Placebo 0.15 0.00 0.00 0.15
001022 Placebo 1.34 0.00 0.00 1.34
001037 Placebo N/A N/A N/A N/A
001004 Placebo 0.00 1.14 0.00 1.14
001024 Placebo 1.62 0.00 0.00 1.62
001035 Placebo 0.00 1.13 2.14 3.27
001027 Placebo 6.58 0.00 0.00 6.58
001008 Placebo 0.00 5.83 0.00 5.83
001026 Placebo 0.00 1.15 7.8 8.95
001019 Placebo 0.00 9.55 40.16 49.71
001020 Placebo 0.00 0.00 20.35 20.35
001014 Placebo 36.73 0.00 0.00 36.73
001029 Placebo 106.2 0.00 0.00 106.2
Change in Index Lesion Surface Area
Subject Randomisation Red Area 
(mm2)
Black Area 
(mm2)
W hite Area 
(mm2)
Total Area 
(mm2)
001001 Valdecoxib -29.02 -1.75 11.62 -19.15
001031 Valdecoxib -10.13 0.00 0.00 -10.13
001005 Valdecoxib 0.00 0.00 -4.27 -4.27
001015 Valdecoxib -3.10 -0.43 0.00 -3.53
001044 Valdecoxib -3.37 0.00 0.00 -3.37
001006 Valdecoxib N/A N/A N/A N/A
001018 Valdecoxib -3.32 0.00 0.00 -3.32
001036 Valdecoxib -2.79 0.00 0.00 -2.79
001045 Valdecoxib 0.00 -0.59 0.00 -0.59
001033 Valdecoxib -0.53 0.00 0.00 -0.53
001012 Valdecoxib -1.10 0.73 0.00 -0.37
001021 Valdecoxib -0.3 0.00 0.00 -0.30
001006 Valdecoxib N/A N/A N/A N/A
001043 Valdecoxib -0.04 0.00 0.00 -0.04
001017 Valdecoxib 0.24 0.00 0.00 0.24
001051 Valdecoxib 0.00 -0.07 0.83 0.76
001010 Valdecoxib 0.00 0.27 0.79 1.06
001002 Valdecoxib 0.00 1.96 0.00 1.96
001030 Valdecoxib 2.52 0.00 0.00 2.52
001025 Valdecoxib 0.00 -3.19 10.18 6.99
001028 Valdecoxib 0.00 21.17 0.00 21.17
001023 Valdecoxib 23.69 -2.33 0.00 21.36
001011 Placebo -15.14 0.00 0.00 -15.14
001048 Placebo -4.94 0.00 0.00 -4.94
001013 Placebo N/A N/A N/A N/A
001046 Placebo -2.75 0.73 0.00 -2.02
001009 Placebo -0.42 0.00 0.00 -0.42
001050 Placebo -0.38 0.00 0.00 -0.38
001003 Placebo 0.00 -0.15 -0.23 -0.38
001007 Placebo -0.33 0.00 0.00 -0.33
001034 Placebo -0.30 0.00 0.00 -0.30
001022 Placebo -0.27 0.00 0.00 -0.27
001037 Placebo N/A N/A N/A N/A
001004 Placebo 0.00 0.11 0.00 0.11
001024 Placebo 0.53 0.00 0.00 0.53
001035 Placebo -0.45 1.11 2.14 2.82
001027 Placebo 3.79 0.00 0.00 3.79
001008 Placebo 0.00 4.02 0.0 4.02
001026 Placebo 0.00 0.48 3.61 4.09
001019 Placebo 0.00 3.85 0.69 4.54
001020 Placebo -3.82 0.00 20.35 16.53
001014 Placebo 36.73 -9.69 0.00 27.04
001029 Placebo 97.87 0.00 0.00 97.87
Appendix 4
Rational for Valdecoxib Dosage
The 40m g / day dosage used was the m axim um  regular daily dosage licensed in the 
British National Form ulary (2002). This was based on the following studies.
Safety / Tolerabilitv / Pharm acokinetics (S/T/PIO
V aldecoxib was evaluated in a  14 day m ultiple dose study at doses up to 40m g tw ice 
daily and an escalating single-dose study up to a m aximum  of 400m g / day where no 
c lin ica lly  sign ifican t adverse  events or labora to ry  abnorm alities w ere observed. 
H ow ever in phase III arthritis trials a  total daily dose 40m g of valdecoxib did increase 
rates o f hypertension and oedem a (i,ii). Patients in the arthritis trials were older and had 
m ore co-m orbidity than those subjects used for dose evaluation studies
In the m ultiple dose trial, steady state levels were reached within one week and the half- 
life was between six to ten hours.
Studies investigating gastrointestinal safety found no difference in incidence of gastric 
ulceration w ithlO m g valdecoxib tw ice daily and 25m g valdecoxib tw ice daily when 
com pared to placebo (iii).
Studies into the effect on p late le t aggression  and bleeding tim e dem onstrated  no 
difference with 10 mg valdecoxib tw ice daily or 25 mg valdecoxib tw ice daily, when 
com pared to placebo (iv,v)
Efficacy
Pooled results of six single dose post surgical studies demonstrated a maximal analgesic 
effect w ith 40m g of valdecoxib. Low er doses provided a sub-m axim al effect and doses 
greater than 40m g provided no additional analgesic effect (vi).
Based on the above inform ation, and the fact that patients in the study would be young 
healthy wom en, it was felt the m axim um  licensed dose would be safe and be m ost likely 
to dem onstrate an effect.
References
i) A  double-blind, placebo controlled, sequential group safety, tolerability and 
pharm acok ine tic  study  o f oral va ldecox ib  in healthy  m ale  subjects. 
G .D .Searle & Co., Protocol No. E 9 1-96-02-002; Report No. E 9 1-00-06-002, 
13 M arch 2000.
ii) R evised report fo r a  double-blind, placebo controlled, single rising dose 
tolerability, safety and pharm acokinetic study of oral valdecoxib in healthy 
m ale subjects. G .D .Searle & Co., Protocol No. E 9 1-96-02-001; R eport No. 
E 9 1-00-16-001, 25 M ay 2000.
iii) A  com parison of the effects o f valdecoxib lOmg bid, valdecoxib 25m g bid, 
naproxen 500m g bid and placebo on the upper gastrointestinal m ucosa in
The work described In chapter 4 The Methodology Study was conducted in 
collaboration w ith ;
Mr Christopher Guyer 
Consultant Gynaecologist 
St Marys Hospital 
Portsmouth
Mr Andrew Pooley 
Consultant Gynaecologist 
New Victoria Hospital 
Kingston
Mr Andrew Kent 
Consultant Gynaecologist 
Royal Surrey County Hospital 
Guildford
Mr Guyer and Mr Pooley captured two pairs of images using the technique 
described with myself in attendance for the first of each of these. Images were 
then sent to Pfizer for storage
Mr Kent captured two pairs of images with me in attendance for both. These 
images were then sent to Pfizer for storage. In addition Mr Kent was the second 
assessor for image analysis to allow assessment of inter observer reproducibility.
Pfizer UK stored all images and provided the software to allow myself and Mr 
Kent to quantify the lesions. Collation of the areas calculated was performed by 
Pfizer.
I was responsible for the design of the study in collaboration with Pfizer as well 
as on site training of ail other collaborators. I recruited patients from the Guildford 
site. I analyzed all images. Data analysis is entirely my own work as are all 
conclusions.
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The work described in chapter 5 The Valdecoxib Study was conducted in 
collaboration w ith ;
Mr Christopher Guyer 
Consultant Gynaecologist 
St Marys Hospital 
Portsmouth
Mr Andrew Kent 
Consultant Gynaecologist 
Royal Surrey County Hospital 
Guildford
Mr J Wright
Consultant Gynaecologist 
The Woking Nuffield Hospital 
Chertsey
Mr A Moors
Consultant Gynaecologist 
Princess Anne Hospital 
Southampton
Design of the study was under taken coliaboratively by Pfizer UK, myself, Mr 
Kent, Mr Pooley and Professor Christopher Sutton
Mr Guyer, Mr Moors and Mr Wright recruited patients from their respective 
hospitals, undertook the surgery, image capture and patient management 
throughout the study. All digital images and tissue samples were sent to Pfizer 
for storage. I visited Portsmouth on three occasions, Chertsey on two occasions 
and Southampton on two occasions to provide training and ensure standardized 
procedures. In addition I was available at all time to deal with any queries. All 
videotapes from these sites were copied by my self at the Guildford site before 
forwarding to Pfizer for storage.
On the Guildford site I undertook all recruitment and screening of patients. All 
surgery and image capture was undertaken by both Mr Kent and my self. All 
patient monitoring was undertaken by myself.
I undertook all lesion analysis at Pfizer UK using the software described, S 
undertook rAFS scoring on ail videos. The second assessor for rAFS scoring 
was Professor Christopher Sutton. Data from all sites was collated at Pfizer UK. 
Data interpretation is entirely my own work as are all conclusions and 
recommendations
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